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Preexposure prophylaxis (PrEP) is an innovative biomedical approach that has been used 
over the past 6 years to avert the spread of human immunodeficiency virus (HIV). Under-
prescribing of PrEP could increase the probability of HIV exposure among 
serodiscordant couples/partners and those who do not practice safe sex. Previous PrEP 
research has not assessed the association between awareness of PrEP, years of experience 
of providers, provider types, and the frequency of PrEP prescription among physicians. 
Precaution adoption model framed this study, which aimed to evaluate the bond between 
the independent variables relating to awareness of PrEP, years of experience, and 
provider types with the outcome of the frequency of PrEP prescription among physicians. 
A cross-sectional design was applied to survey 100 physician participants. Kendall's tau-
b correlation test and Fisher’s exact test were used to analyze the research questions. 
Eighty-seven percent of the surveyed physicians had low awareness about PrEP, and 90% 
never prescribed PrEP. Lack of awareness was the primary barrier to prescribing PrEP at 
the providers’ level. Kendall's tau-b correlation test showed that higher awareness of 
PrEP and years of experience were associated with the frequency of PrEP prescription at 
95% confidence interval. However, Fisher’s exact test showed an insignificant difference 
between provider types and the frequency of PrEP Prescription. These findings support 
the notion that independent of specialty, the more physicians know about PrEP and the 
more years of experience they have, the more they prescribe it. The results and 
recommendations could enhance positive social change by providing information to 
develop an inclusive PrEP education curriculum for health care professionals.  
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Chapter 1: Introduction to the Study 
Introduction 
The human immunodeficiency virus (HIV) is still among the top three public health 
concerns in the United States (Centers for Disease Control and Prevention [CDC], 2013a). 
Despite the large amounts of money and steady effort put into research and prevention programs, 
the United Stated registers 50,000 new HIV cases yearly (CDC, 2013a).  HIV preexposure 
prophylaxis, (PrEP) is a revolutionary, novel biomedical intervention in the last 6 years. For 
different reasons, using PrEP to prevent HIV makes sense (World Health Organization, WHO, 
2013). For example, antiretroviral therapy (ART) has 96% efficacy against HIV transmission to 
the uninfected people who are at higher risk. These individuals include serodiscordant partners, 
men who have sex with men (MSM), needle-sharing drug users and sex workers (CDC, 2013a; 
Rosenthal et al., 2013; Wade, et al., 2013). However, Cairn (2013) reported that physicians do 
not prescribe PrEP very often in some geographic areas because they lack information about it.  
In this chapter, I first present background information, including ignorance about and 
barriers to using PrEP, conflicting perceptions about PrEP, the high cost of PrEP and health 
insurance, and the need for further PrEP studies. Then I cover the following topics: problem 
statement, the purpose of the study, research questions and hypotheses, theoretical/conceptual 
framework for the study, its nature, definitions, assumptions, limitations, scope, and 
delimitations, and the significance.  
Background 
According to Cairns (2013), Truvada, the primary PrEP medication is underprescribed in 
the United States since its approval in 2012 by the U. S. Food and Drug Administration (FDA). 





(CDC, 2013a; Rosenthal et al., 2013; Wade et al., 2013). Only 2,000 doses were prescribed 
nationally in 2013, and less than 1% was used for prophylactic purposes. Cairns showed that 
among authorized PrEP prescribers, only 37% prescribed it. This underprescription could have 
been due to a lack of knowledge about PrEP it.  
Ignorance About, and Barriers to, PrEP  
People who are exposed to HIV and therefore need PrEP are not only unaware of being 
exposed but are also unaware of existing PrEP services. Many people in serodiscordant 
relationships are unaware of PrEP (Mijiti et al., 2013).  A study in Xinjiang, China, showed that 
97.2% of participants (all of whom were in serodiscordant relationships) had never heard about 
PrEP (Mijiti et al. 2013). Brooks et al., (2011) ran a semistructured qualitative research study and 
identified three barriers to PrEP: excessive cost, fear of side effects, and fear of the need for 
lifetime use. Brooks et al. also identified two factors that recommend PrEP: freedom from having 
to use condoms and freedom from fear about HIV infection. There is a significant link between 
awareness about PrEP and a higher desire to use PrEP (Young, Li, & McDaid, 2013). More than 
70% of HIV specialists are likely to prescribe PrEP if they have a positive perception of it (Puro, 
Palummieri, De Carli, Piselli, & Ippolito, 2013).  
Conflicting Perceptions About PrEP  
Puro et al. (2013) stated that there are conflicting attitudes towards, and 
perceptions about PrEP. Some patients believe that HIV specialists are more likely than 
primary care providers to prescribe Truvada for HIV treatment of HIV-positive patients 
(Cairns, 2013). Others believe that HIV specialists are less likely than primary care 
providers to prescribe Truvada to prevent HIV in HIV-negative populations (Cairns, 





because providers believe that PrEP is toxic and that patients would prefer behavioral 
interventions to biomedical interventions (Cairns, 2013; Puro et al., 2013). Thus, there is 
a significant association between the undesirable attitudes towards prescribing PrEP and 
the misinformation about PrEP. 
High Cost of PrEP and Health Insurance 
According to Horberg and Raymond (2013), the cost of PrEP and its coverage by health 
insurance are factors that influence providers’ decisions to prescribe it. They stated that the high 
cost of PrEP can dissuade its prescribers and users. PrEP-related expenses include medications, 
laboratory, and professional fees. Some indirect costs are those related to the providers’ training 
and treatment of adverse drug events. In their study, Horberg and Raymond estimated the total 
cost for the first year of HIV PrEP for private funders was over $17,000. Private insurance 
companies cover HIV PrEP that their associates have prescribed (i.e., providers with whom they 
are in a care management partnership). Their study also revealed that, under the Affordable Care 
Act, PrEP coverage varies accordingly to the available qualified health insurance plans. The 
Ryan White program, a government health care initiative that helps with the cost of medication 
covers HIV medication only for HIV-positive individuals. Other public health coverage 
programs, including Medicare, and Medicaid, the leading coverage programs for HIV 
prescriptions in the United States, do not cover PrEP. Exploring the cost of PrEP and its 
coverage issues in depth in further studies is desirable.   
Further Studies on PrEP 
First, many global health organizations recommended research on HIV prevention, and 
vaccines. These international institutions include United Nations International Children's 





of these organizations agreed that the time had come to promote universal accessibility to HIV 
prevention and treatment services. Second, further studies are needed to detect gaps in PrEP 
provision. Further studies could address the following topics: PrEP implementation technical 
problems, barriers to prescribing PrEP, compliance with the PrEP regimen, the conflicting 
relationship between PrEP and the use of condoms, PrEP ethical issues, PrEP and HIV law, and 
policy. These studies are necessary to address gaps in the integrated treatment and prevention 
approach to HIV (Treatment Action Group (TAG), 2013). Third, counseling and educational 
interventions are essential to boost efforts to publicize PrEP (Brooks, et al., 2011). Fourth, 
detailed HIV PrEP guidelines need to be developed to improve physicians’ readiness to provide 
PrEP and behavioral interventions to people at risk for HIV infection (Puro, et al., 2013). That 
said it was apparent that multisector studies of PrEP could provide insights to improve its 
implementation. These studies could target clinical, social, economic, cultural, and policy 
implications (Albert, Warner, & Hatcher, 1998). 
Problem Statement 
Individuals who refuse to practice abstinence or use condoms, persons in serodiscordant 
relationship, and sex workers also belong to the population at higher risk for HIV infection 
(Albert, Warner & Hatcher 1998; Civic & Wilson, 2013). Even though some health insurance 
companies cover HIV PrEP (Hoberg, 2013; Liu, et al., 2014), physicians are reluctant to 
prescribe it (Krakower & Mayer, 2013). What remains unknown is why.  
Purpose of the Study 
This survey study was an attempt to investigate the barriers to prescribing HIV PrEP and 
the need for education among care providers in the Quad Cities in Illinois and Iowa. I examined 





as predictors of the frequency of PrEP prescription among care providers. A better understanding 
of the knowledge, behavior, and attitudes of physicians regarding the PrEP will better indicate 
where additional education may be needed. Three independent variables (awareness of HIV 
PrEP, the number of years of service as a primary care provider or HIV specialists, and provider 
type), and one outcome variable (frequency of PrEP prescription) were analyzed to test the 
hypotheses.  
Nature of the Study 
Study Variables 
The outcome variable or dependent variable in this study was the frequency of PrEP 
prescription. The independent variables included HIV PrEP awareness, the number of years of 
service as a primary care provider or HIV specialist, and the difference between provider types. 
The three independent variables were split into multiple levels (i.e., dummy variables), and there 
was only one dichotomous outcome variable (i.e., the frequency of PrEP prescription: low versus 
high). These conditions justified the applicability of the logistic regression analysis to this study. 
I also included some secondary variables (i.e., covariates) such as gender (i.e., male versus 
female), geographic location (i.e., Iowa versus Illinois) and HIV specialist versus a non-HIV 
specialist. I used SPSS software to analyze the data. Multiple logistic regression (regression on 
dummy variables), analysis of variance (ANOVA) and analysis of covariance were used to 
answer the hypotheses. Logistic regression was suitable to examine whether there was a 
difference between provider types (i.e., family practitioners, pediatricians, internists, 
obstetricians/gynecologists, and infectious disease/HIV specialists) and the outcome variable 





within the research population groups as opposed to the difference between them (CERG 
Resources, n. d.).   
Study Design 
I used a cross-sectional design to explore whether there is an association between the 
independent variables and the outcome variable. Cross-sectional design helps inquirers to 
establish a relationship between the research variables. It also offers an opportunity to select 
random participants who provide representative data to explain the study variables (Frankfort-
Nachmias & Nachmias, 2008). The cross-sectional design fit this quantitative study that 
generated numerical and broad data to describe the research problem. The quantitative methods 
help the researcher to describe the relationship between the study variables through statistical 
analysis (Creswell, 2009). 
I designed my survey, so I needed to pilot test my survey instrument. A minimum of 
eight returned surveys was desirable (i.e., 42.11% response rate) to accept the result as valid. To 
do so, I selected 10% of my 185 estimated sample size including the primary care providers and 
HIV specialists to participate in the pilot test. In essence, I needed 19 participants for my pilot 
study. I also needed a minimum of 78 returned surveys corresponding to 80% confidence 
interval to accept the results of the actual study as valid. My plan to reach that goal was to 
increase the sample size. I started the survey with 185 participants (i.e., 119 corresponding to 
95% power increased by 54%). The breakdown was 74 family practitioners, 21 pediatricians, 57 
internists, 18 obstetricians/gynecologists, and 15 infectious disease / HIV specialists.  The 
calculated sample size was 119 for 95% power to which I added 54% to increase the response 
rate (Table 2). I added the 15 of the 17 physicians from the infectious disease subpopulation to 





participants from the actual study to avoid the sampling related biases. I collected data through 
self-administrated paper-based survey questionnaires. The pilot test step was vital to ensure the 
validity of the survey instrument before the actual study data collection. 
Research Questions and Hypotheses 
Three research questions and their allied null and alternative hypotheses guided this 
study. 
Note that provider type is an independent variable composed of five dummy variables: 
family practitioners, pediatricians, internists, obstetricians/gynecologists, and infectious 
disease/HIV specialists. 
Research Question 1: What is the association between HIV PrEP awareness and the 
frequency of PrEP prescription among primary care providers and HIV specialists in the Quad-
Cities? 
Ho1: There is no association between HIV PrEP awareness and the frequency of  
PrEP prescription among primary care providers and HIV specialists in the Quad-Cities. 
 Ha1: There is an association between HIV PrEP awareness and the frequency of  
PrEP prescription among primary care providers and HIV specialists in the Quad-Cities. 
 
Research Question 2: What is the association between the number of years of service as a 
primary care provider or HIV specialist and the frequency of PrEP prescription among primary 
care providers and HIV specialists in the Quad-Cities? 
Ho2: There is no association between the number of years of service as a primary 
care provider or HIV specialist and the frequency of PrEP prescription among primary care 





Ha2: There is an association between the number of years of service as a primary  
care provider or HIV specialist and the frequency of PrEP prescription among primary care 
providers and HIV specialists in the Quad-Cities. 
 
Research Question 3: What is the association between provider types and the frequency 
of PrEP prescription among primary care providers and HIV specialists in the Quad-Cities? 
Ho3: There is no association between provider types and the frequency of PrEP 
prescription among primary care providers and HIV specialists in the Quad-Cities.   
Ha3: There is an association between provider types and the frequency of PrEP 
prescription among primary care providers and HIV specialists in the Quad-Cities. 
 
Theoretical or Conceptual Framework 
PrEP services have played a significant role in preventing HIV-negative individuals from 
HIV infection. Other HIV prevention programs combine behavioral, biomedical, and structural 
interventions (Underhill, Operario, Mimiaga, Skeer, & Mayer, 2011). Public health professionals 
have identified numerous theoretical frameworks that apply to the HIV prevention field. Many of 
those theories like precaution adoption process model (PAPM) are useful to define PrEP-related 
concepts.  
Developed by Janis and Mann in 1977, PAPM explains the process in individuals’ 
decisions making and the conversion of the decision into action in seven stages (Glanz, Rimer, & 
Viswanath, 2008). The first stage is the unawareness of the health issue phase. In the second 
stage, people learn about the problem for the first time but feel not concerned about it. The third 





thinking about the responses. At this point, people can decide to stay at this stage or resolve to do 
nothing. This category of people falls under Stage 4 and “halting” PAPM. The third possibility is 
to move to the next Stage 5 through precaution adoption. Stage 6, behavior initiation phase, 
allows people to acting. The last, Stage 7, is when people maintain their new behavior over time 
(Glanz, et al., 2008, p.126).  
 Lack of information about PrEP is often associated with PrEP underprescription among 
care providers (White, Mimiaga, Krakower, & Mayer, 2012). The focus of this study was to 
explore HIV/AIDS health-protective behaviors by determining how primary care providers and 
HIV specialists make decisions to prescribe PrEP and how they translate their decisions into 
actions. For this reason, it was appropriate to adopt the PAPM as a theoretical framework and the 
concept of implementation intentions to guide this study.  
PAPM allows inquirers to identify the stages that people go through when they start 
“health protective behaviors” (Glanz, et al., 2008). It also provides indicators that help 
researchers to determine the factors favoring behavior change from one stage to another (e.g., 
from awareness to action). The model allowed me to identify barriers to PrEP provision at each 























Figure 1. Visual representation of PAPM constructs showing the relationship between 
implementation intentions concept and the gaps in HIV PrEP Prescription. Adapted from 
“Integrated Precaution Adoption Process Model and Implementation Intentions Concept Applied 
to Breast Cancer Screening,” by K. K. Engelman, A. P. Cupertino, C. M. Daley, T. Long, A. 
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underserved communities to bridge the mammography divide. Copyright 2011 by Engelman et 
al., licensee BioMed Central Ltd.  
 
Applying Gollwitzer’s (2006) implementation intentions concept to this study helped me 
examine how PrEP service implementation intentions can enhance the primary care providers 
and HIV specialists’ willingness to prescribe it. The implementation intentions are a goal-
directed behavior where people perform behavior B if they met a condition C (Gollwitzer & 
Sheeran, 2006). The concept is effective in enhancing past behavior that leads to the prediction 
of new behavior (Orbeil, Hodgldns, & Sheertan, 2014). If it is applied, the concept can help 
primary care providers and HIV specialists to meet their PrEP prescription goals. Gollwitzer 
(n.d.) explained the concept as a motivation driver for individuals to adopt healthy behavior. The 
connection between the study variables and precaution adoption process model constructs is 












 Independent variables  Outcome 
variable 
  HIV PrEP 
awareness 





 Frequency of 















 Stage 1: 
Unaware of Issue 
 Never heard 
of  HIV PrEP        
 As a factor 
leading to that 
situation 
 As a factor 
leading to that 
situation 
 Stage 2: 
Unengaged by 
issue 
 Never thought 
about prescribing 
HIV PrEP 
 As a factor 
leading to that 
situation 
 As a factor 
leading to that 
situation 
 Stage 3:    
Undecided about 
acting  




 As a factor 
leading to that 
situation 
 As a factor 
leading to that 
situation 
  Stage 4:  
Do not want to 
act 
(Table continues) 




 As a factor 
leading to that 
situation 
 
 As a factor 








constructs   
 HIV PrEP 
awareness 





 Frequency of 
HIV PrEP  
prescription 
 Stage 5: 
Decided to Act 
                            
Plan to prescribe 
HIV PrEP 
 As a factor 
leading to that 
situation 
 As a factor  
leading to that 
situation 
 Stage 6: Acting  Prescribing HIV 
PrEP 
 As a factor 
leading to that 
situation 
 As a factor 
leading to that 
situation 
 Stage 7: 
Maintenance 
 Prescribing HIV 
PrEP 
 As a factor 
leading to that 
situation 
 As a factor 
leading to that 
situation 
 
Definition of Terms 
Antiretroviral therapy (ART): It consists of the use of the retroviruses inhibitors drugs to 
treat HIV. It is also known as highly active antiretroviral therapy (AIDS info, 2008). ART 
combines three or more HIV drugs that act on different stages of HIV life cycle (AIDS info, 
2008). 
Biomedical interventions:  HIV prevention techniques, biomedical interventions consist 
of the use of clinical, medical, and public health prevention methods to reduce physiologically 
and biological risk factors for HIV infection (Effective Interventions, 2012). They help to 





(Effective Interventions, 2012). In addition to the vaccine, preventive treatments and males’ 
circumcision, the biomedical interventions include sexually transmitted infections (STIs) 
treatment and diaphragm use (Mayer, Margie Skeer, & Mimiaga, 2010). 
HIV preexposure prophylaxis (PrEP): It is HIV drug-based preventive intervention that 
allows HIV-negative persons who are vulnerable to HIV infection to use antiretroviral drugs like 
Truvada to reduce HIV transmission risks (AIDS info, 2008).  
Primary care providers: Health care practitioners, primary care providers play a medical 
caring role in the community by offering preventive care and healthy lifestyle education services 
to their patients (MedlinePlus, 2014). Their primary tasks are to diagnose and treat common 
medical conditions and refer clients to specialists as needed (MedlinePlus, 2014). Primary care 
providers include physician assistants, nurse practitioners, family practitioners, internists, 
pediatricians and obstetricians/gynecologists  
Serodivergent relationship: The concept describes the situation where an HIV-negative 
person is in sexual relation with his or her HIV-positive partner. The other terms that describe 
these kinds of relationships include serodiscordant, discordant, magnetic or HIV-
positive/negative (AIDS.gov, 2012).  
Assumptions 
 Although the FDA has approved PrEP drugs like Truvada, PrEP for HIV prevention was 
underprescribed by physicians in the Quad Cities area. I assumed that awareness about PrEP, the 
number of years in the medical field, and provider types have an influence on PrEP prescription 






 Proactively, it is important to foresee additional HIV PrEP education for primary care 
providers and HIV specialists in the Quad Cities area. The data that I collected were from 
doctors. Data from assistant physicians and nurse practitioners might not reflect their attitudes 
regarding PrEP prescription because they work under the supervision of others doctors.  
Scope and Delimitations 
In this study, I focused on PrEP prescription effectiveness in the Quad Cities 
Illinois/Iowa. The barriers to prescribing PrEP were assessed at the physicians’ level only. I 
delimited the research to a quantitative, cross-sectional study design. The study participants were 
family practitioners, pediatricians, internists, obstetricians/gynecologists, and infectious 
disease/HIV specialists, who were practicing. They must live in the geographic area of 70 miles 
radius from Rock Island city in Illinois as of May 15
th
, 2015. I excluded physician assistants and 
nurse practitioners from this study. The independent variables were limited to the PrEP 
awareness, the number of years of service as a primary care provider or HIV specialists, and 
provider’s type. The unique outcome variable in this study was the frequency of PrEP 
prescription. The study included some demographic variables like gender, age, and geographical 
location (living in Iowa versus Illinois or urban versus rural). Race and religious beliefs were 
other independent variables that could be used in this study, and therefore could be considered 
exploratory in nature in explaining the lack of PrEP prescription among care providers. 
However, they were excluded to keep the study simple.   
I chose the word barriers over causes and knowledge for two reasons. First, the word 
barrier aligns to the research problem.  The study was about identifying the factors that can 
explain HIV PrEP under prescription at the prescribers’ level to recommend further educational 





cross-sectional survey study, I only explored the association between variables. Therefore, it was 
not appropriate to investigate the cause and effects relationship in this study. Furthermore, the 
word knowledge gives readers the impression that I focused on HIV PrEP prescription awareness 
only. In the title, I preferred the expression HIV PrEP to the name Truvada because Truvada is a 
component of PrEP. Moreover, Truvada has both treatment and preventive functions whereas 
PrEP is a prophylaxis procedure. Prevention is the best strategy to limit HIV infection (Mayer, et 
al., 2010). Thus, using PrEP helped me to narrow the study to HIV prevention among HIV-
negative populations that are highly exposed to HIV infection. 
Limitations  
Some intentional and unintentional biases can raise questions regarding the ability of 
one’s research to provide valid and trustful results (Creswell, 2009). The potential biases in this 
study that I was working on included the following: 
1- Participant selection (i.e., there are fewer HIV specialists in the research geographic 
area than other groups that fall under primary care specialties). This type of bias can 
create an underrepresentation of HIV specialists in the study sample population. I 
used a proportional sampling method to avoid the participant selection bias. 
 
2- It is also possible to perceive PrEP for certain subpopulations more than others or 
assuming that HIV specialists are better off in terms of PrEP awareness and prescribe 
more PrEP than other primary care providers. Being aware of that allowed me to be 






3- Nonresponse and low participation rates could be potential threats to my research 
validity. I increased my sample size by 54% to mitigate that problem. Soriano (2013, 
p. 91) suggested an increase in the research population sample size by 43% as a 
solution to low participation rates issue in a study. I selected 185 then increased that 
to 300 subjects for my study. Developing understandable survey instruments can help 
to reduce nonresponse  
 
 
4- Biases can also arise from researcher’s experience. I examined some research 
parameters like PrEP prescription or low PrEP literacy as good or not because of my 
background in HIV/AIDS field. Being aware of the problem alerted me to be neutral. 
I interpreted and concluded on the study results and findings based on the outputs 
from valid and reliable data collection instruments and statistical tests only. 
 
 
5- The perceived efficacy of PAPM to conceptualize PrEP awareness and provision 
could constitute a theory bias in the study. Sampson Jr., (2012) acknowledged theory 
bias in a study when one perceived the efficiency in certain constructs to 
conceptualize research problems. I worked closely with my chair and committee 
members to minimize all theory related biases.  
Significance 
PrEP is an HIV prevention biomedical intervention within the primary health care setting, 
as opposed to specialized care. The rate of new HIV incidences is still alarming inside and 
outside of the United States (Krakower & Mayer, 2012). Since HIV is still rampant in the world, 





settings becomes a must. The results and findings of this study could provide CDC and other 
international public health organizations like WHO with valuable information to develop 
detailed guidelines for PrEP education and service. Various insights from this study could help 
providers determine effective PrEP guidelines and related services, and in turn, limit the risk of 
HIV proliferation in the community. The study could inspire public health practitioners to 
develop a suitable education approach to improving PrEP literacy among health care providers. 
Educating people about PrEP is vital to arose positive social change regarding stimulating a 
universal access to PrEP services. This study also helped to understand how and why primary 
care providers and HIV specialists underprescribed PrEP in the studied geographic area. I 
explored the lack of PrEP prescription contributing factors like low PrEP literacy, the number of 
years of service in the medical field and provider types. Finally, the findings and 
recommendations provided insights to improve HIV/AIDS policies. 
Summary 
The lack of funding for antiretroviral and the difficulty of monitoring HIV PrEP clients 
were some barriers to HIV PrEP prescription among HIV specialists (Puro et al., 2013). The 
information above was a benchmark against which I compared the study results based on the 
information that I collected from primary care providers and HIV specialists. Combined with 
other behavioral interventions, when it is suitable, PrEP reduces the risk of HIV infection in 
HIV-negative populations. For this reason, consistent efforts should be made to enhance HIV 
PrEp prescription among HIV specialists and primary care providers (Golub, Gamarel, Rendina, 
Surace, & Lelutiu-Weinberger, 2013). In this research, I examined the association between HIV 
PrEP awareness, the number of years of service as a primary care provider or HIV specialist, 





In Chapter 2, I discuss existing peers review literature on HIV PrEP, literature search 
strategies and HIV PrEP-related issues and concepts. Following the literature review, I describe 
the research methods in Chapter 3, present the research findings in Chapter 4, and in Chapter 5, 







Chapter 2: Literature Review 
Introduction 
Essential to this research is the concept that people perform behavior B if they met a 
condition C (Gollwitzer & Sheeran, 2006). There are the plethora of studies of HIV epidemics as 
well as studies of approaches that have been applied to mitigate its occurrence (CDC, 2011). The 
combination of the behavioral and biomedical interventions is a successful evidence-based 
approach of controlling HIV propagation (CDC, 2011). However, the education based on 
abstinence and condom use only has shown its limits in reducing the risks of HIV infection 
(CDC, 2013b). PrEP regimen is recommended to HIV-negative people who might be at higher 
risk for the HIV infection like serodivergent couples/partners (AIDS.gov, 2012). Many studies 
and publications have contributed to HIV PrEP-related literature in the last 6 years. The purpose 
of this literature review is to explore various studies on PrEP to inform the background of my 
research topic and identify gaps in the literature. I highlight the gaps upon which this study was 
designed to justify the conduct of this study to the reader. 
Literature Search Strategy 
 The key terms that I used for the web search entry included HIV pre-exposure 
prophylaxis, HIV PrEP, HIV PrEP guidelines,and Truvada prophylaxis HIV (Duncan & 
Duncan, 2012). I also used PrEP Prescription, HIV PrEP prescription frequency, HIV PrEP, 
cost and insurance, and HIV PrEP Literacy for internet search. I searched literature through 
many Walden University Library databases such as Medline, Academic Search Alumni 
Edition, Journal of American Medical Association, Pubmed, and Health Sciences: An SAGE-
Full Text Collection and CINAHL Plus. Google Scholar allowed me to search for PrEP fact 





information resources to explore official PrEP guidelines and protocols. They allowed me to 
explore studies, conference reports, and other publication on PrEP. I filtered the search by peer 
review articles after the publication date of 2010. 
Literature Review on the Concepts and Key Variables  
Understanding PrEP 
PrEP is an HIV prevention regimen for HIV-free persons prone to ongoing substantial 
“risk of HIV infection” (Aids.gov, 2014). It consists of one pill of Truvada daily as a preventive 
measure to reduce HIV transmission risks (AIDSinfo, 2008). Truvada is “a combination of 
emtricitabine and tenofovir disoproxil fumarate,” both belonging to the HIV nucleoside reverse 
transcriptase inhibitor drugs that stop HIV from making copies. Its dosage for PrEP requires 
“200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate” in a single pill 
(Choopanya et al., 2013). Truvada can be (a) used with other antiretroviral drugs to treat HIV-
positive patients and (b) used alone to prevent HIV infection in HIV-negative populations. When 
taken consistently, it has decreased the risk of HIV transmission among HIV-negative 
populations (Choopanya et al., 2013). Truvada is a component of PrEP that is a routine 
procedure. PreP regimen has four implementation phases. The first consists of assessing 
significant risk for HIV infection. The second is about establishing PrEP candidates’ eligibility 
clinically (i.e., documented HIV-negative status, documented hepatitis B virus 
infection/immunization status, and checking for (a) no contraindicated medication, (b) no signs 
of severe HIV infection, and (c) healthy liver and good functioning kidneys). The third consists 
of prescribing Truvada (a steady oral dose of Truvada on the daily basis). The fourth is a follow-
up. The follow-up services include every 3 months or 6 months for HIV and STI tests, 





clean needles/syringes exchange, and substance abuse treatment services (Smith, 2014). The 
CDC recommended PrEP in addition to the following: 
- Consistent and correct use of condoms, 
- Getting tested periodically for HIV and sexually transmissible diseases,  
- Adopting less risky sexual behaviors, and  
- Using sterilized drug injection equipment or participating in a drug treatment program 
(Aids.gov, 2014). 
 
Effectiveness and Awareness of PrEP  
Every new drug has to be proven safe and effective before its commercialization (FDA, 
2014). The effectiveness of HIV PrEP is a point of debate, with many misconceptions about its 
implementation (Wade et al., 2013). Because understanding PrEP regimen related issues are in 
flux, it is important to update readers on the current publications and studies of the HIV PrEP. 
Choopanya, et al. (2013) found tenofovir disoproxil fumarate effective to reduce HIV infection 
risks down to 49%, (95% CI, 9.6 to 72.2; p = 0.01). Paltiel et al. (2009) conducted a cohort study 
on the effectiveness of PrEP among MSM in the United States. The study provided data for a 
computer-stimulated HIV infection and care as an archetype of PrEP. The results showed PrEp 
effective to decrease the risk of HIV infection up to 19% down and to improve patients’ mean 
life expectancy by 0.8% (Paltiel, et al., 2009).  
Care providers should know more about HIV PrEP (Rosenthal, et al., 2013). White, et al. 
(2012) conducted two successive online survey studies separated by 4 month period interval with 
N = 178 and N = 115 respectively for the physicians in Massachusetts. The results showed an 





of the surveyed physicians believed that formal PrEP guidelines from CDC would increase their 
readiness to prescribe PrEP (White, et al., 2012). The problem of PrEP unawareness has crossed 
the United States’ borders. Rosenthal et al. (2013) conducted a cross-sectional study of HIV-
positive clients to assess PrEP awareness level of the physicians in France. The study targeted 23 
representative infectious diseases and internal medicine departments.  Only 41.8% of the 
surveyed people aware of the PrEP, and about 8.3% declared that they had discussed PreP 
information with their friends and relatives (Rosenthal et al., 2013). Duncan and Duncan (2012) 
found Google.co.uk and Bing to be popular search websites where people have access to HIV 
PrEP information. In this section, I covered HIV PrEP effectiveness and its awareness level 
among potential PrEP candidates and physicians, which had not been linked to reporting in the 
literature for the Quad Cities in Illinois.  
 
Challenges of Prescribing PrEP  
Prescribing PrEP could be challenging to some care providers because of the divergent 
view on it (Puro et al., 2013). HIV specialists have different attitudes towards and insights 
regarding prescribing PrEP (Puro et al., 2013).  In 2012, Puro et al. conducted a survey study 
with N = 311 of HIV specialists selected through a convenience sampling method to explore HIV 
specialists’ attitudes and perceptions about prescribing PrEP in Italy. They used participants’ 
readiness to prescribe PrEP as a criterion to classify them into two groups (i.e., people who have 
positive and those who have negative views about PrEP). They applied univariate and 
multivariate regression analysis to assess the relationship between different attitude towards 
PrEP prescription and certain factors.  The results illustrated the contradictory attitudes towards 





optimistic attitudes towards PrEP and were willing to prescribe it. On the another hand, 30% had 
a negative view about PrEP. Puro et al. also found an association between the insufficient 
information, potential toxicity and cost, and underprescription of PrEP. Their study also revealed 
an association between the lack of provision of information, concerns about toxicity, lack of 
formal guidelines, and the positive or negative attitudes of HIV specialists towards PrEP 
prescription. 
Providers did not prescribe PrEP to their patients very often in the United States. 
Krakower and Mayer (2013) reported in a study that only 4% of participants had prescribed 
PrEP. Among 43% of HIV/AIDS specialists, who admitted that they had received HIV PrEP 
prescription requests from their patients, only 19% had prescribed it. Before PrEP initiatives, 
HIV prevention strategies included condom promotion, perinatal interventions, male 
circumcisions, and harm reduction interventions (CDC, 2013a). CDC (2013) remarked that 
despite these prevention efforts, the United States experienced around 50,000 new HIV 
infections in 2013. PrEP is effective in preventing HIV infection (CDC, 2013a; Rosenthal et al., 
2013; Wade et al. 2013). However, the illiteracy about PrEP can lead to its underprescription 
(Castillo, 2013). Many researchers found a substantial association between primary care 
providers’ PrEP knowledge and increased PrEP prescription (Kalichman, Ramachandran & Catz, 
1999; Young, Li & McDaid, 2013). 
Mansergh, Koblin and Sullivan (2012) addressed PrEP implementation challenges for 
MSM and their communities. Some of the challenges include misapprehension of PrEP, charges, 
possible epidemiological effects, lack of suitable PrEP messaging, and inadequate usage of PrEP. 
Jay and Gostin (2012) also published an article that identified many ethical challenges such as 





cost, and drug dependency associated with HIV PrEP. Naswa and Marfatia (2011) raised the 
same concerns about PrEP. Furthermore, Golub et al. (2013) found a significant association 
between free access to PrEP and (a) a sense of protection, (b) PrEP acceptance, and (c) PrEP 
adherence. Thus, it is imperative to identify and address the challenges appropriately to make 
PrEP services affordable.  
The above studies did not address PrEP prescription attitudes and perception among 
primary care providers who can prescribe PrEP. They also did not include HIV PrEP education 
needs. Those gaps in the literature justify the relevance of my dissertation topic. 
 
HIV PrEP Education and Literacy Improvement Needs 
Education is the key strategy to enhance PrEP literacy. Krakower and Mayer (2012) 
stated that the higher HIV infection incidence rate in the United States requires multilevel 
prevention approaches including PrEP education enhancement within care providers. In articles 
review study, Krakower and Mayer evaluated primary care providers’ knowledge about PrEP. 
They used five indicators (a) attitudes to identify potential PrEP clients, (b) PrEP counseling 
skills, (c) PrEP drug monitoring abilities, (d) the level of understanding antiretroviral drug 
resistance, and (e) HIV transmission process to assess health care providers’ PrEP literacy level. 
The study allowed Krakower and Mayer to portray the need for additional education on HIV 
PrEP for the primary care providers. It is important to develop PrEP curricula and programs for 
health care professionals and clients to solve HIV PrEP low literacy problem. According to 
Jukkala et al. (2009), improving primary care providers’ PrEP use for HIV prevention could 





 In addition, the acceptance of PrEP is often associated with the clients’ health literacy 
level (Barragán et al., 2005). In a prospective survey study with 372 participants at an urgent 
care center, Barragan et al., (2005) evaluated whether there is an association between 
participants' health literacy and their readiness for HIV screening. The finding showed that low 
literacy level clients were more likely than high literacy level clients to accept HIV testing. 
Drainoni et al., (2008) also found that HIV health literacy was vital for both HIV-positive 
patients and care providers. Young et al., (2013) conducted a cross-sectional study with 1,515 
gay and bisexual men. They explored the relationship between knowledge of and willingness to 
use PrEP and readiness to participate in a PrEP research in Scotland. The findings showed a 
significant relationship between awareness of PrEP and rose in the clients’ readiness to use PrEP 
(Young et al., 2013). 
The reviewed literature provides insights for better understanding of HIV PrEP issues. It 
contains arguments and empirical data that support the idea of enhancing primary care providers’ 
HIV health literacy to ensure a smooth transition between the shifts from HIV/AIDS special care 
to the primary care settings. However, there are still gaps in the literature regarding the 
identification of subsequent research theory that will help to depict PrEP under prescription 
behavioral mainstream issues that were not addressed through educational interventions in the 
Quad Cities. For that reason, I use PAPM to determine the factors that explain the behavior 
displayed by the providers under each of the seven stages of the PAPM regarding their attitude 
towards PrEP Prescription. 
 





When used properly, the HIV PrEP regimen can protect people at higher risk of getting 
HIV (Scheibe, 2012). Despite this indication, the lack of a PrEP guideline could lead to its 
misuse, and the existence of several PrEP guidelines could be confusing and lead to chaos in the 
PrEP implementation process. In 2011, the CDC mentioned the lack of a comprehensive PrEP 
implementation guidelines and the nonexistence fixed PrEP protocol. Significant data from many 
PrEP studies allowed the CDC to develop interim guidance for PrEP prescription to at higher 
risk for HIV populations (CDC, 2011; Scheibe, 2012). 
PrEP interim guidance developed by CDC (2011) included (a) the necessity to prescribe 
HIV PrEP to at higher risk heterosexual adults and (b) the prohibition to prescribe TDF/FTC 
(Truvada) as PrEP for HIV-positive clients. The interim guidance also endorsed the mandatory 
use of HIV PrEP for serodiscordant couples who planned to have a baby (CDC, 2013a). 
Furthermore, the interim guidance encouraged women to prove their pregnancy status through a 
documented pregnancy test to be eligible to start the HIV PrEP regimen. It required care 
providers to discuss PrEP benefits and risks with women who plan to have a baby before PrEP 
initiation. It required a mandatory submission of pregnancy information about PrEP clients to the 
Antiretroviral Use in Pregnancy Registry. The guidelines also recommended physicians inform 
clients about the Truvada adherence. To PrEP prescribers, reporting PrEP adverse effects to the 
FDA's MedWatch is a must (CDC, 2011). The CDC developed PrEP prescription guidance for 
MSM population. According to CDC, the regulation requires steady updates as needed.  
An updated interim guideline for PrEP, published by the CDC in 2013b, authorized the 
institutionalization of PrEP services in intravenous drug users’ services. It also banned PrEP 
prescription to individuals who have a creatinine clearance level less than 60 ml/min (CDC, 





HIV infection” (CDC, 2013b). It recommended that physicians monitor the behaviors that can 
put their clients at higher risk for HIV infection and control their HIV and pregnancy status 
routinely (CDC, 2013b). 
 The WHO, (2012) developed a document that recommended evaluating and grading the 
evidence for serodiscordant status among couples or partners before prescribing PrEP to the 
potential clients. It suggested HIV PrEP use as additional prevention intervention for the 
uninfected partners in the countries where HIV infection arise among serodiscordant 
couples/partners (WHO, 2012). Scheibe (2012) also developed an HIV PrEP guideline for 
Southern Africa countries. There is a need for further investigations to assess the impact of the 
multiple HIV PrEP prescription guidelines on its implementation in the practice. 
 
HIV PrEP and Stigma 
People could become refractory to PrEP if they are stigmatized. The effects of stigma on 
the use of HIV PrEP were diversely appreciated (Smith, et al., 2012). Smith et al. (2012) stated 
that it is crucial to know whether stigma will enhance the status of people who use PrEP or not. 
Kenworthy and Bulled (2013) examined the ethical issues surrounding PrEP services in the 
developing country (Lesotho). They showed that there were many disparities in the distribution 
of PrEP services in the world and that stigma is associated with underprescription of PrEP. HIV 
prevention through PrEP initiatives needs effective structural and institutional support to reduce 
HIV PrEP-related stigma (Wheelock, et al., 2012).  
The frequency of PrEP prescription is distributed disproportionally across the United 
States. Cairns (2013) found that physicians in the Northern America prescribe more HIV PrEP 





The reasons that explain these disparities were not assessed in the Cairns’ study. However, the 
study is of an inspirational relevance for further researches on PrEP.  
Promoting PrEP could have an undesirable impact on other HIV prevention behavioral 
interventions such as abstinence and the use of condoms and vice versa. Wade et al., (2013) 
developed the key themes that could assist researchers while investigating the impact of the 
behavioral interventions on HIV PrEP. The themes included (a) the motivations to use PrEP, (b) 
barriers to PrEP use, (c) facilitators to PrEP use, (d) sexual decision-making in the context of 
PrEP, (e) prospective PrEP education content, and (f) perceived effective characteristics of PrEP 
delivery personnel (Wade, et al., 2013). These themes could be adapted as a survey instrument to 
assess patients’ willingness to accept PrEP and or providers’ readiness to prescribe it. Golub et 
al., (2013) showed that more than 55% of the surveyed MSM and transgender women were 
ready to use PrEP services. Numerous are the studies that investigated PrEP awareness, 
acceptance and use within diverse populations. Those studies targeted MSM, serodiscordant 
couples/partners, sex workers, and needle-sharing drug users (CDC, 2013d; Rosenthal et al., 
2013; Wade et al., 2013). However, none of the studies has explored PrEP literacy among 
primary care providers, and HIV specialists. More specifically, no research that targeted primary 
care providers and HIV specialists had been done to assess their PrEP prescription frequency in 
the Quad Cities Area in the United States. 
Literature Review on the Theoretical Foundation  
The PAPM has been applied to many studies in the public health field. Glanz, Rimer, & 
Viswanath, 2008 cited several studies that used PAPM. For example, they mentioned Blalock, 
DeVellis, Giorgino et al. (1996) who applied PAPM to their prevention of osteoporosis study. 





framework for their study of mammography issues. They finally give credit to Weinstein & 
Sandman (2004) who adopted PAPM in a study of home radon testing problems. Costanza et al., 
(2007) also used PAPM in a colorectal cancer study. It was applied to a comprehensive sexual 
education study (Stanger-Hall, 2011) and to a cyberbullying study (Chapin, 2014). The PAPM 
has also been used for modeling HIV prevention efforts (Jacobson, 2010), preventing HIV in the 
aging population (Jacobson, 2010), and explaining HIV serodiscordant experiences (Lelaka, 
2014). Most of the studies that used PAPM have generated quantitative cross-sectional data 
(Block et al. 1996; Chapin, 2014; Costanza, et al. 2007; & Lelaka, 2014). The literature review 
provided additional evidence for why PAPM theory was a good choice for this study.  
Literature Review on the Methods Used in Previous PrEP Studies  
Among all research methods, the quantitative cross-sectional survey has been the most 
applied to the studies on HIV PrEP (Duffus, 2011 & Whiteside, Harris, Scanlon, Clarkson, 
2014). Whiteside, et al. (2014) used a cross-sectional design to examine “the self-perceived risk 
of HIV and attitudes about PrEP” in STD clinics in South Carolina (United States). They 
recruited 405 clients by using convenience-sampling methods. They gave a $20 gift card as an 
incentive to each surveyed person upon the survey completion. Furthermore, they used SAS 
version 9.2 to treat the research data and a multivariable logistic regression model to analyze the 
effect of the demographic variables on the participants’ attitudes about PrEP. Finally, they used 
ordinal logistic regression models to assess the differences in PrEP perceptions among different 
groups. Leonardi, Lee, and Tan, (2012) used a survey approach to examine awareness of PrEP 
and the participants’ preparedness to use HIV PrEP in Toronto, Canada. They collected data 





They run several statistical analysis tests including exploratory logistic regression models, 
multivariate logistic regression model, and the multivariate model. 
This literature review explored HIV PrEP effectiveness and awareness, HIV PrEP 
prescription and challenges, HIV PrEP education and literacy improvement needs, guidelines for 
PrEP prescription, and HIV PrEP stigma. I examined some studies and articles related to the 
PAPM, the theoretical framework of this study. I also reviewed the methods applied to other 
HIV PrEP studies.  
It appeared that none of the reviewed articles and texts discussed how awareness of PrEP, 
providers’ years of experience and provider types influence the frequency of PrEP prescription 
among primary care providers and HIV specialists in the Quad Cities. This study scrutinized 
whether there is an association between the independent variables and the outcome variable. The 
results helped me to justify the following assumptions: 
1. The more providers know about HIV PrEP, the higher frequency of PrEP prescription 
will be.  
2. The more years of experience providers had, the higher frequency of PrEP 
prescription will be.  
3. Being a primary care provider versus HIV specialist may increase the frequency of 
PrEP prescription.  
 
Summary and Gaps in the Literature 
The existing literatures that have explored HIV PrEP intervention present the fact that 
PrEP is effective (CDC, 2013; Wade, Mayer, Elsesser, Mimiaga, O'Cleirigh, & Safren, 2013). 





among physicians (Krakower, & Mayer, 2012). There were three of the studies that examined 
HIV PrEP underprescription problems (Cairns, 2013; Golub, Gamarel, Rendina, Surace, & 
Lelutiu-Weinberger, 2013; Krakower & Mayer, 2013). Other studies demonstrated that HIV 
PrEP acceptance is often associated with people’s health literacy level.   
Evidence from the literature revealed that no study investigated the frequency of HIV 
PrEP prescription among primary care providers, nor assessed the barriers of HIV PrEP 
prescription at primary care providers’ level exclusively in the Quad Cities. In addition, none of 
the existing studies have used the PAPM theoretical framework to explain the barriers of HIV 
PrEP prescription. I remarked that multiple logistic regression is commonly used in HIV PrEP 
studies that I explored. However, none of the reviewed articles has used the logistic regression 
on dummy variables, multiple linear regression or analysis of variance (ANOVA) as statistical 
analysis tools. These gaps in the literature and methodology motive me to explore the elements 
that have a bearing on PrEP prescription so that public health education efforts can be tailored to 
fill the gaps. The next chapter of this dissertation proposal not only details the research 








Chapter 3: Research Method 
Introduction 
In this study, I scrutinized whether the frequency of PrEP prescription among primary 
care providers and HIV specialists is associated with PrEP awareness, the number of years of 
service, and provider’s types respectively. Explicitly, I explored the barriers to HIV PrEP 
prescription and education needs among care providers. The setting was the great Quad Cities 
area up to 70 miles radius from the city of Rock Island in Illinois. One hundred physicians 
participated in the study. I used the Internet research tools to search for an updated list of primary 
care providers and HIV specialists practicing in the Quad Cities for May 15, 2015 as an ample 
frame. I (a) defined in deep the study population (i.e., the whole set of significant units of 
analysis), (b) explained the sample design (i.e., the subset of the study population), (c) 
determined the sample size (i.e., subgroup of sampling units from a research population; 
Frankfort-Nachmias & Nachmias, 2008, pp.162-185), and (d) used SPSS and G*power analysis 
tools for potential statistics tests. In this chapter, I discuss the research design and the 
justification for its use for this study. I also discuss the target population and setting, research 
parameters, estimated sample size, and the participants’ eligibility criteria. Next, I provide 
information on the instrumentation, data collection, and statistical methods. Additionally, I 
discuss the threats to internal, external, and constructs validity. The chapter ends with a summary 
preceded by the discussion on the ethical procedures.  
Design and Approach 
The method of inquiry for the study was descriptive, a cross-sectional quantitative study 
of barriers associated with the frequency of PrEP prescription among primary care providers, and 





the medical field and the provider types were assessed. For the independent variables, the 
frequency of HIV PrEP prescription was analyzed to test the following questions and 
hypotheses: 
Question 1: What is the association between HIV PrEP awareness and the frequency of  
PrEP prescription among primary care providers and HIV specialists in the Quad-Cities? 
H01: There is no association between HIV PrEP awareness and the frequency of  
PrEP prescription among primary care providers and HIV specialists in the Quad-Cities. 
Ha1: There is an association between HIV PrEP awareness and the frequency of PrEP  
prescription among primary care providers and HIV specialists in the Quad-Cities. 
Question 2: What is the association between the number of years of service as a primary 
care provider or HIV specialist and the frequency of PrEP prescription among primary care 
providers and HIV specialists in the Quad-Cities? 
H02: There is no association between the number of years of service as a primary 
care provider or HIV specialist and the frequency of PrEP prescription among primary care 
providers and HIV specialists in the Quad-Cities. 
Ha2: There is an association between the number of years of service as a primary care 
provider or HIV specialist and the frequency of PrEP prescription among primary care providers 
and HIV specialists in the Quad-Cities. 
Question 3: What is the difference between provider types and the frequency of PrEP 
prescription among primary care providers and HIV specialists in the Quad-Cities? 
H03: There is no difference in providers’ type and the frequency of PrEP prescription 
among primary care providers and HIV specialists in the Quad-Cities.   





among primary care providers and HIV specialists in the Quad-Cities. 
 
Justification for Using This Design and Approach 
The cross-sectional design allowed me to use questionnaires to collect information from a 
random sample of primary care providers regarding their attitude and experience towards PrEP 
prescription at one in time. Frankfort-Nachmias and Nachmias (2008) stated that cross-sectional 
design is not only appropriate to describe the association between variables but also to ask 
survey participants questions about their attitudes, backgrounds, and experience. In addition, the 
cross-sectional design offers wide data collection tools including electronic mail and paper-based 
surveys through mail questionnaires (Hall, 2008) that I used as data collection methods. Hall 
(2008) acknowledged that the survey is one of the most common data collection techniques for 
cross-sectional designs. A cross-sectional design is open to different data collection methods 
including the Internet, face-to-face interviews, self-administrated/mailed questionnaires, and 
phone interviews (Hall, 2008). Whiteside et al. (2014) applied a cross-sectional design to HIV 
PrEP study in STD clinics. Despite its applicability to various studies, a cross-sectional design 
has some methodological limitations. Some weaknesses of the cross-sectional design include 
non-response biases associated to low response from the participants and the difficulty of 
estimating the research outcome precisely with a small sample size (Barratt & Kirwan, 2009).  I 
addressed the weaknesses by selecting a large sample size to increase the response rate. 
Methodology 
Target Population and Setting 
The study population included primary care providers who can prescribe in the Quad 





Genesis Group, Trinity Unity Care, and other medical groups’ facilities). The sampling units 
included prescription drug prescribers (i.e., family practitioners, pediatricians, internists, 
obstetricians/gynecologists and infectious disease/HIV specialists). The sampling frame was 
based on the available updated online lists of the primary care providers operating within 70 
miles radius of the City of Rock Island as of May 15, 2015. The search criteria included (a) 
Sorting by the distance within 70 miles radius from the city of Rock Island and (b) specialty.   
Research Parameters   
The research parameters included HIV PrEP awareness, the number of years of service, 
and the provider types as predictors for the frequency of PrEP prescription. The study targeted 
the cities of Davenport, Bettendorf, Clinton, De Witt, Wilton, Le Claire, Muscatine, Blue Grass, 
Eldridge, Orion, and Durant, Iowa City, in Iowa. I also included Rock Island, Milan, Silvis, East 
Moline, Moline, Alpha, Cambridge, Fulton, Cordova, Colona, Aledo and Coal Valley, Peoria, in 
Illinois. In this study, I examined five subpopulations including, family practitioners, 
pediatricians, internists, obstetricians/gynecologists and infectious diseases physicians including 
HIV specialists. The last sub-population served as a control stratum for comparison purpose. 
The potential PrEP prescribers accounting for the five sampling subpopulations included 
440 family physicians, 106 obstetricians/gynecologists, 341 internists, 124 pediatricians, and 17 
infectious disease/HIV specialists. There were 963 physicians working in the area as of May 15, 
2015 from which, I selected the sample population through appropriate probability sampling 
methods. I projected to use the physicians’ list available at the Illinois Department of Public 
Health as a supplement to the sampling frame to avoid incomplete sampling frame error. 





some sampling units from the list.  The survey response rate is often very low among physicians 
(Kellerman & Herold, 2001; Pit, VO, & Pyakurel, 2014; VanGeest, Johnson, & Welch, 2007).  
 
Sample Size 
I ran G*Power software to calculate the sample size. Power analysis allows researchers to 
derive the sample size and sample size estimate for a study (Trochim, 2006a). It consists of 
running the F-test (i.e., linear multiple regression fixed model with R-square deviation from 
zero). I took into account the parameters for two-tailed analysis like effect size f square of 0.15, 
an alpha of 0.05, and an input power of 80%, 90% or 95% as needed. The three predictors 
involved in this analysis are HIV PrEP awareness, the number of years of service, and the 
differences in specialties. The results for 80% power shows N of 78, N of 100 for 90% power, 
and N of 119 for 95% power. I started with N= 120 (i.e., given by 95% power) plus additional 
54% (i.e., plus 65 = 185 total) preliminary participants. The graphs below show the results from 









Figure 2.  Using G*Power graphs to generate the sample size. 
For the confidence interval (CI) = 80%, the graph showed sample size N = 78; for a CI = 90%, 
the graph showed N = 100; for a CI = 95%, the graph showed N = 120.  
 
Since the sample size was determined, I set the 18% proportion strategy to determine the 
sample size for each stratum. If a stratum has a population < 20, the entire population was taken 
into account, and the 18% proportion is not applied. I summarized the breakdown of the sample 
size per provider type in Table 2. Next, I verified the representativeness of the sample size based 
on the size of an acceptable standard error calculation. This process is the obligatory path to 
determine the accuracy of the study results. I incorporated the values of the effect size, power, 







Breakdown of the Sample Size per Provider Type 
 Provider types  Number in the 
sample frame per 70 
miles radius from the 
city of Rock Island 




Projected sample size 
per provider type 
 Family practitioners  440 16.63% proportion 74 
 
 Pediatricians  124 16.63% proportion 21 
 Internists  341 16.63% proportion 57 
 Obstetricians/ 
 Gynecologists  
106 16.63 18 
 Infectious     
disease/HIV  
specialists  
17 Not applied* 17 - 2* = 15 
 Total 1,028 16.63% proportion 170 
 Actual total sample 
size is  
74+21+57+18+15*    = 185 
 
Note. *Proportion not applied if the total population in the stratum is less than 20.  






I requested a change in the procedure, and I was authorized by the IRB committee to 
increase the number of participants from 185 to 300 to scale up the response rate close to 30% 
that was found during the pilot study. I added 23 participants to each subpopulation group shown 
on the preliminary breakdown of the actual study population group. The final breakdown showed 
97 (74 + 23) family practitioners, 44 (21 + 23) pediatricians, 80 (57 + 23) internists, 41 (18 + 23) 
obstetricians/gynecologists, and 38 (15 + 23) infectious disease/HIV specialists. 
 
Eligibility Criteria for Participants 
 Participants were registered and licensed physicians who practiced in the geographical 
area defined previously as of May 15, 2015. They must have belonged to an infectious diseases 
specialty or any of the types of physicians that fall under primary care practice. They included 
family practitioners, pediatricians, internists, obstetricians/gynecologists, and infectious 
disease/HIV specialists.  
 
Characteristics of the Selected Sample 
The sample design of the study was a proportional stratified random sample with five 
strata: family practitioners, pediatricians, internists, obstetricians/gynecologists, and infectious 
disease/HIV specialists. The population consists then of N = N1+N2+N3+N4+N5 with N1 
family doctors, N2 pediatricians, N3 internists, N4 obstetrician/gynecologists, and N5 infectious 
disease/HIV specialists. Knowing the definite number in each stratum, I selected a proportional 
sampling fraction of 18% from each stratum. Next, I applied the simple random sampling 
procedure to each list to select the participants for the study. Overall, I began with proportionate 
sampling strategies by stratifying the population into appropriate subcategories and then took a 





subcategory, was identical to their proportion in the study population (Wadsworth Cengage 
Learning, 2005). However, I expanded the sample size to all individuals in the strata that 
contained less than 20 people to avoid obtaining a low response from one group. I also used very 
aggressive follow-up strategies including mailing reminders and in-person doctors’ office visits 
to collect the completed questionnaires.  I also planned, if necessary, to give a blank 
questionnaire to those who might lose their early questionnaire for immediate completion during 
the on-site follow-up visits.  
Instrumentation 
In this section, I focused on the questionnaire that I used to collect my data. I divided the 
questionnaire into six fragments. The first fragment contained three questions related to the 
demographic information (i.e., area zip code, gender, and age). The second part consisted of one 
closed-ended question. A set of eight answers was offered to choose that most closely reflects the 
level of participants’ awareness of PrEP. The third category also had one closed-ended question 
on the frequency of PrEP prescription. Participants were offered a set of eight responses and 
have had to choose one that most describes how often they prescribe PrEP. I built the fourth, 
fifth, and sixth groups of questions on the similar model. The respondents were offered multiple 
choices of answers and were asked to choose one answer that most closely describes their 
opinion. The questionnaire covered the number of years of service as a primary care provider or 
as HIV specialist, the difference in specialties, PrEP prescription attitudes, and barriers 
respectively (Appendix A).  
I used the modified Glanz et al. (2008) PAPM stage clarification algorithm to develop the 
survey questions. It helped me to investigate the first null hypothesis: There is no association 





as an outcome among primary care providers and HIV specialists in the Quad Cities. I 
represented the modified algorithm to clarify PAPM stage in the Table 3. 
Table 3 
Modified PAPM stage Algorithm to Assess PrEP Awareness 
Questions and answers Corresponding PAPM 
stage 
1. Have you ever heard about HIV Pre-exposure Prophylaxis 
(PrEP)? 
No 
Yes [go to question 3] 
Stage 1 
2. Have you ever prescribed PrEP to a client? 
 
Yes 
No, [go to question 3] 
Stage 6 
3. Which of the statements below describes better your opinions 
about prescribing PrEP? 
I have never thought about prescribing PrEP to clients           
I am undecided about prescribing PrEP to clients                
I am resolved to not prescribe PrEP to clients                








 Source. Adapted from “Precaution Adoption Process Model: Stage Classification Algorithm,” by K. 
Glanz, B. K. Rimer, & K. Viswanath, 2008, Health Behavior and Health Education:  
Theory, Research, and Practice (4th Ed.), p. 136. Copyright 2008 by John Wiley & Sons, Inc.  







Glanz et al., (2008) used the algorithm to describe how Weinstein et al., (1998) applied 
PAPM to their home radon testing study in Columbus, Ohio. The algorithm not only inspired me 
to develop the questionnaire but also assisted me during data interpretation process. Next, I 
tested the questionnaires for reliability and validity through a pilot study.  
Pilot Tests 
I needed a minimum of eight returned surveys (i.e., 42.11% response rate) to consider the 
pilot test result as valid. To reach that goal, I started the survey with 19 physicians (i.e., 10% of 
N = 185 projected for the main study) to avoid nonresponse bias. The breakdown of the 19 
participants is as follow, 6 family practitioners, 3 pediatricians, 4 internists, 4 
obstetricians/gynecologists, and 2 infectious disease/HIV specialists. I passed out the self-
administered questionnaire to the participants. I asked them to give me feedback in writing 
format regarding items and instructions that they found unclear or difficult to understand. I 
involved my Chair, my second committee member, and the Institutional Review in the pilot test 
process monitoring to ensure that the process was compliant with the standards. A copy of the 
questionnaire is inserted in Appendix A.   
Data Collection and Analysis  
I collected quantitative, categorical data including nominal and ordinal data in this 
study. I gathered primary data through the self-administered paper-based survey. I used the 
United States’ postal mailing system to distribute the questionnaires. I mailed the survey to185 
physicians at the beginning. I needed minimum 78 of returned surveys corresponding to 80% 
confidence interval to accept the results as valid. My plan to reach that goal was to increase the 





95% confidence interval increased by 54%). In addition, I included a survey monkey link in the 
mail for those who might not be comfortable with mailing back the survey. A questionnaire 
cover letter and a stamped return envelope were included in the mailing.  
The study had one ordinal outcome (i.e., the frequency of HIV PrEP prescription). Also, 
it had two nominal independent variables (i.e., HIV PrEP awareness and the difference in 
provider’s type), and one ordinal independent variable (i.e., the number of year of service). I 
included individuals (e.g. persons who can prescribe HIV PrEP), and groups (e.g. different 
medical specialties) as the research units of analysis. In a study, the unit of analysis is who or 
what about which an investigator may generalize (Long, 2013). I have planned to ask for PrEP 
prescription records from the Illinois and Iowa Department of Public Health. However, I 
aborted that option for confidentiality reasons.  
I used SPSS statistical software to analyze data. I conducted a descriptive statistics 
analysis to generate the data summary. In addition, I applied statistical analyses to test the 
hypotheses. The variables that I considered in the descriptive statistics were age, gender, the 
number of year of service, and the frequency of HIV PrEP prescription. The statistical analysis 
section consisted of determining the suitable statistical test for each of the three research 
questions.  
I projected to apply the logistic regression to analyze the research question 1: What is the 
association between HIV PrEP awareness and the frequency of PrEP prescription among primary 
care providers and HIV specialists in the Quad Cities? The eight levels associated with the 
independent variable (HIV PrEP awareness) included very much, much, quite a bite, a little, very 
little, none, don’t know and no answer (Appendix A). I grouped these parameters in a 





know and no answer and aware for the responses that fall under very much, much, quite a bite, a 
little. For the research question 2: What is the association between the number of years of service 
and the frequency of PrEP prescription among primary care providers and HIV specialists in the 
Quad Cities, I planned to use logistic regression analysis too. It offered the opportunity to group 
the predictor years of service into binary variables coded as fewer years of experience for 
physicians who have less than five years of experience and more years’ experience for those who 
have more than five years of experience in medical field.  
I projected to apply the ANOVA to the research question 3: What is the difference 
between provider type (i.e., family practitioners, pediatricians, internists, 
obstetricians/gynecologists, and infectious disease/HIV specialists) and the frequency of PrEP 
prescription among primary care providers and HIV specialists in the Quad Cities? In a study, 
the investigators use ANOVA when they want to determine whether specific groups have unlike 
effects (Barnes, & Writer, 2012). More specifically, ANOVA was suitable to determine whether 
belonging to each of the groups (i.e., family practitioners, pediatricians, internists, 
obstetricians/gynecologists, and infectious disease/HIV specialists) means higher or low HIV 






Statistical Analysis Plan and Results Reporting Strategy of the Research Variables  
 Variables that I intended to collect Source Nature  
 Frequency of HIV PrEP 
prescription 
Cross- Sectional Survey of 
Physicians  
Review of archived medical 
reports available at the local or 
State Department of Public Health 
Continuous/Categorical (Ordinal) 
 HIV PrEP awareness Cross- Sectional  
Survey of Physicians  
Categorical (Nominal) 
 Number of year of service: 
 Zero to five years   
 Five to ten years  
 10 to 15 years 
 15 to 20 years  
 20 years and more  
Cross- Sectional  
Survey of Physicians  
 
Categorical (Ordinal) 
 Difference in provider type 
 Family practitioners  
 Pediatricians  
Internists 
Obstetricians/Gynecologists 
Infectious Disease/HIV specialists  
Cross- Sectional  
Survey of Physicians  
Internet-based search and  
official list of physicians available at 

















After the survey data have been collected, I entered them into Excel database. I created 
an SPSS data file to run multiple logistic regression analysis. SPSS allowed me to investigate 
the association between the independent variables (i.e., PrEP awareness level and the number 
of years spent as a prescriber in the medical field). It was a useful tool to test the null 
hypotheses one and two (i.e., 1. There is no association between HIV PrEP awareness and the 
frequency of PrEP prescription among primary care providers in the Quad Cities; and 2. There 
is no association between the number of years of service and the frequency of PrEP 
prescription among primary care providers in the Quad Cities). For each variable of interest, I 
projected not only to calculate unadjusted odds ratios and 95% confidence intervals for in 
across-group comparisons purpose, but also I planned to include a p-value < 0.05 in the 
multivariate model. I also looked at a combined model to determine whether all three 
independent variables predict PrEP prescription.  
I projected the logistic regression test for the research question1: What is the association 
between HIV PrEP awareness and the frequency of PrEP prescription among primary care 
providers and HIV specialists in the Quad Cities? The analysis consisted of collecting data by 
using eight levels break down of the independent variable or predictor (i.e., awareness levels: 
Very much, much, quite a bit, a little, very little, none, don’t know, and no answer). I collected 
data on multiple levels independent variables or predictors and one outcome variable (Green & 
Salkin, 2011). There is one independent variable (X = HIV PrEP Awareness with eight 
dummies) and one outcome (Y = Frequency of HIV PrEP prescription). Since I used non-
experimental methods, it is appropriate to call X and Y respectively as a predictor and the 





PrEP awareness score to predict the frequency of HIV PrEP prescription among primary care 
providers and HIV specialists respectively.  
I also planned to use the logistic regression to analyze the research question 2: What is 
the association between the number of year of service and PrEP prescription frequency among 
primary care providers and HIV specialists in the Quad Cities? In this question, the variable 
year of service was divided into five groups. I coded the groups in dichotomous variables, 
fewer years of experience and more years of experience. I represented the groups in the 
following format, 0 to 5 years of service for those fall under fewer years of experience in 
medical field and the remaining, 5 to 10 years of service, 10 to 15 years of service, 16 to 20 
years of service, and 21 years and more fall under more years of experience in medical field.  
First, I checked for the assumptions of logistic regression. An assumption is a condition 
that allows a researcher to aware of the effectiveness of what he or she attempts to do. In a 
study, the assumptions must be met to avoid statistical analysis biases (Field, 2012). The first 
assumption was whether the variable follow the normal distribution. The second assumption 
included additivity and linearity. For example, the dependent variable and dummy variables 
will not be estimated accurately when non-linear interactions occur in the terms of relationship 
(Osborne & Waters, 2002). Consequently, the true associations will be underestimated, and 
cause Type I and Type II errors. Therefore, it was important to examine the residual plots to 
detect an eventual nonlinearity (Osborne & Waters, 2002). The third assumption was the 
reliability of the variables’ measurement (i.e., there is no measurement error). The fourth 
assumption was about the homoscedasticity or homogeneity of variance (i.e., one has the same 





I planned to apply the ANOVA to Question 3: What is the difference between provider 
type (family practitioners, pediatricians, internists, obstetricians/gynecologists and infectious 
disease/HIV specialists) and the frequency of PrEP prescription among primary care providers 
and HIV specialists in the Quad Cities? The five dummy variables that fall under the predictor 
(i.e., provider type) include  
1. Family Practitioners (X1) 
2. Pediatricians (X2) 
3. Internists (X3) 
4. Obstetricians/Gynecologists (X4), and 
5.  Infectious Disease/HIV specialists (X5).  
I run the ANOVA F test to evaluate the magnitude of the difference between the group 
means on the frequency of PrEP prescription from each other group. I checked for the 
following assumptions: Normal distribution of the dependent variable for each dummy 
variable, same variances of the dependent variable for all dummy variables, and the 
independence of the cases and the scores on the test variable. The violation of the independence 
assumption could cause ANOVA F test to yield inaccurate p-values (Green, & Salkind, 2011).  
Later, I projected to run a post hoc test (Tukey’s HSD) to determine which specific groups 
differ.  
Since the outcome (i.e., the frequency of HIV PrEP prescription) is an ordinal variable 
that is associated with the three independent variables, I can use the nonparametric tests to 
analyze the research hypotheses. Field (2013) stated that researchers use the nonparametric 
tests for ordinal data in a study where fewer assumptions were made. He précised that the 





interpretation tool. In another hand, the parametric statistic tests involved interval and ratio data 
with normally predictable distribution (Field, 2013).  
The two nonparametric tests that could be applied to this study are Wald-Wolfowitz 
runs and Mann-Whitney tests. Wald-Wolfowitz runs are suitable for the first hypothesis: There 
is no association between HIV PrEP awareness and the frequency of PrEP prescription among 
primary care providers and HIV specialists in the Quad Cities. It was convenient to look for 
runs of scores from each of the primary providers and HIV specialists’ group within the ranked 
order (Field, 2013) respectively.  
I planned to use Mann-Whitney tests for the second null hypothesis: There is no 
association between the number of years of service as a primary care provider and the 
frequency of PrEP prescription among primary care providers and HIV specialists in the Quad 
Cities. This test was appropriate when researchers want to look at, in the “differences in the 
ranked position of scores in different groups” (Field, 2013)   
Mann-Whitney tests model could also be applied to analyze the third null hypothesis, 
H0: There is no difference in family practitioners, pediatricians, internists, 
obstetricians/gynecologists and infectious disease/HIV specialists and PrEP prescribing habits 
among primary care providers and HIV specialists in the Quad Cities. I run the different tests 
mentioned. The trustfulness and the confidence of the research results depended on the 
inquirer’s ability to control and evaluate potential threats to validity (Gast &Ledford, 2014). I 
presented the statistical analysis plan on Table 5 and the summary of the statistical analysis and 













Nature of the questions Statistical tests 




















number of year 











modal values or as 
central tendency, 
variability and shape 
Descriptive 
analysis 





















Nature of the questions Statistical tests 









place data in  






 is the 
association 













Relate more than 2 
variables coupled with 
group comparison 
within 1 independent 
variable with dummy 
(8 levels break  
down of PrEP 
awareness  
(i.e.,Very much, much, 
quite a bit, a little, very 
little, none, don’t know 
and no answer) and 1 
dependent variable (the 
frequency of PrEP 
prescription). It 
expresses the degree of 























Nature of the questions Statistical tests 





Create and label 

















What is the 
association 
between the 
number of years 
of service as a 
primary care 
provider or HIV 
specialists and 






specialists in  
the Quad-Cities? 
The question relates 5 
combinations of the 
predictor, years of service 
(i.e., Zero to five years, 
five to ten years, ten to 15 
years, 15 to 20 years and 
20 years and more) to one 
dependent variable (the 
frequency of PrEP 

































Nature of the questions Statistical tests 





 Question 3: 

























(provider type) with 
one quantitative 
dependent variable (the 

















Table 6  
Summary of the Statistical Analysis and Justifications 
Research Questions Projected Statistical Analysis Justifications 
Research Question 1: 
What is the association 
between HIV PrEP 
awareness and the 
frequency of  
PrEP prescription 
among primary care 
providers and HIV 
specialists in the Quad-
Cities? 
Logistic Regression  
 
Researchers performed this analysis 
on a binary dependent variable (DV) 
and binary independent variables 
(IV). 
It presents many advantages 
including (a) help to predict on DV 
from the ID data; (b) it is easier to 
calculate and interpret the odds ratio 
for a better understanding of the 
predictors. 
 
The research question involves a 
binary (dichotomous) DV and 
dichotomous independent 
variables. 
Code for DV: 
Low frequency = 0;  
High frequency = 1 
Code for IV: 
Unaware = 0;  
Aware = 1 
Logistic regression analysis is a 
stable and powerful model. Not 
only it helps researchers to 
represent intervals or levels but 
also increases the probability of 
events. 
Research Question 2: 
What is the association 
Logistic Regression The research question involves a 
binary DV and dichotomous 
   





   
Research Questions Projected Statistical Analysis Justifications 
between the number of 
years of service as a 
primary care provider 
or HIV specialists and 
the frequency of PrEP 
prescription among 
primary care providers 
and HIV specialists in 
the Quad-Cities? 
Researchers performed this analysis 
on a dichotomous dependent 
variable (DV) and dichotomous 





Code for DV: 
Low frequency = 0;  
High frequency = 1 
 
Code for IV:  
less (< 5) = 0;  more (> 5) = 1 
Research Question 3: 
What is the difference 
between provider types 
and the frequency of 
PrEP prescription 
among primary care 
providers and HIV 
specialists in the Quad-
Cities?  
Analysis Of Variance (ANOVA) 
Post hoc test 
 
Researchers used ANOVA when 




The question involves five groups 
(i.e., family practitioners, 
pediatricians, internists, 
obstetricians/gynecologists and 
infectious disease/HIV specialists). 
There are more than two means to 
compare. Using multiple t-tests 
might be too complicated. I use 
ANOVA to avoid conducting 
multiple t-tests. Also, ANOVA 
will allow me to gather all the data 





Threats to Validity 
The extent to which a researcher measures, what he or she plans to measure effectively, is 
referred to as “validity” (Frankfort-Nachmias & Nachmias, 2008). Frankfort-Nachmias and 
Nachmias also mentioned that it is crucial, in quantitative inquiry, to provide steady evidence to 
support whether the variable measuring tools that one uses are reliable. It is also important to 
control and evaluate the study’s internal, external and construct validity threats (Creswell 2009; 
Frankfort-Nachmias & Nachmias, 2008; Gast &Ledford, 2014).  
Internal validity is about the causal effect attribution of the dependent variable on the 
independent variable (Frankfort-Nachmias & Nachmias, 2008). The threats to internal validity 
include any factor that can trigger researchers’ ability to make sound inferences from the 
research data (Creswell, 2009).  Some of the internal validity threats can arise from participants’ 
selection methods, history, compensatory rivalry, testing, and instrumentation (Creswell, 2009). I 
limited the internal validity threats by selecting participants randomly and by reducing 
expectations of the HIV specialists versus primary care providers. It is also important to create 
equality between different subgroups involved in a quantitative study and to use the same 
instrument for each sub-group (Creswell, 2009). Researchers were also concerned about the 
effect of the variable on “other natural settings and on the large populations” (Frankfort-
Nachmias & Nachmias, 2008) to ensure the study’s external validity.  
External validity stressed on the generalizability of research to the large population (Gast 
&Ledford, 2014).  External validity threats can occur through improper inferences process that 
links data to participants, different settings and situations (Creswell, 2009). The external validity 
threats may include various interactions between (a) selection and treatment, (b) setting and 





claims among the subpopulation in which the generalization of the study results is limited and by 
engaging participants from different settings in the study (Creswell, 2009). In addition, I planned 
to replicate the same research to compare the results to the actual study in future. It is also 
indispensable to evaluate the compliance of the data collection instrument to “the concepts and 
the theoretical assumption” (Frankfort-Nachmias & Nachmias, 2008) of the study by controlling 
the threats to construct validity. 
Construct validity allows researchers to prove the alignment of the study instruments to 
the theoretical framework (Frankfort-Nachmias & Nachmias, 2008). For instance, Frankfort-
Nachmias and Nachmias cited Miltron Rokeach (1960) who developed a dogmatism 
questionnaire to assess the association between close-mindedness and ideological orientations. It 
is capital to establish convergent and discriminant validity of the study. Convergent validity 
consists of illustrating that the measures that were expected to be related were related effectively. 
Discriminant validity ensures that the measures that were expected to be different were not tied 
one to another as expected (Trochim, 2006c).   
 Ethical Procedures 
Researchers’ primary responsibilities are to be obedient to ethical standards and to 
behave properly as far as the research involves human beings (Rudestam & Newton, 2007). This 
study was strictly anonymous and confidential. For example, while sending e-mails, I protected 
participants’ addresses by using Blind Carbon Copy. I also reminded participants to not put their 
returning address on the envelop containing their feedback letter. I included the invitation to 
participate in research letter coupled with implied consent statement, Wiley Global permissions 
to adapt PAPM algorithm for Figures 1 and Table 2 in Appendix B and Appendix C respectively, 





I addressed potential ethical issues regarding the study process and recruitment materials 
by alerting my Chair as the issues arise. I was also obedient to the Walden University’s research 
ethical standards. I had exclusive access to the data, which I stored in a secured location. For 
example, the printable documents were kept in a locked cabinet. I also used a password protected 
computer and back up on the password protected jump-drive. Data would be deleted according to 
the timeframe allowed by the school standards. Finally, I disclosed any conflict of interest (i.e., 
dissertation study grants, the work environment) and justified the use of any incentives to 
encourage participants (if it is applied) to ensure a better turnout of the survey.  
 
Summary 
In this chapter, I provided general information about the methodology of the study. The 
information was about the research design, the target population, the setting, research 
parameters, sample size, eligibility criteria, and instrumentation. I not only discussed the 
approaches to the analysis of the research variables but also discussed the statistical methods to 
test the research questions and hypotheses. Multiple logic regression analysis and Non-
parametric statistics test if necessary were projected to be used to assess the extent of the 
association between independent variables and the outcome variable of interest. I further 
discussed the potential internal, external, and the constructs validity threats to the study. The 
chapter ended with an overview of the ethical procedures. In Chapters 4 and 5, I analyze the data 
collection process through the cross-sectional survey among primary care providers and HIV 





 Chapter 4: Results 
Introduction 
In this study, I aimed to understand the barriers to prescribing HIV PrEP among primary 
care providers and HIV specialists using the independent variables of PrEP awareness, the 
number of years of service, and provider’s types. I also included gender, and geographic 
situation. These sociodemographic variables may predict the frequency of PrEP prescription 
(outcome variable) among primary care providers and HIV specialists. I described the research 
questions and hypotheses as follows: 
Research Question 1: What is the association between HIV PrEP awareness and the 
frequency of PrEP prescription among primary care providers and HIV specialists in the Quad-
Cities? 
Ho1: There is no association between HIV PrEP awareness and the frequency of  
PrEP prescription among primary care providers and HIV specialists in the Quad-Cities. 
Ha1: There is an association between HIV PrEP awareness and the frequency of PrEP  
prescription among primary care providers and HIV specialists in the Quad-Cities. 
Research Question 2: What is the association between the number of years of service as a 
primary care provider or HIV specialist and the frequency of PrEP prescription among primary 
care providers and HIV specialists in the Quad-Cities? 
Ho2: There is no association between the numbers of years of service as a primary 
care provider and the frequency of PrEP prescription among primary care providers and HIV 





Ha2: There is an association between the numbers of years of service as a primary care 
provider and the frequency of PrEP prescription among primary care providers and HIV 
specialists in the Quad-Cities. 
Research Question 3: What is the difference between provider types and the frequency of 
PrEP prescription among primary care providers and HIV specialists in the Quad-Cities? 
Ho3: There is no difference in provider types and the frequency of PrEP prescription 
among primary care providers and HIV specialists in the Quad-Cities.   
Ha3: There is a difference in provider types and the frequency of PrEP prescription 
among primary care providers and HIV specialists in the Quad-Cities. 
 The results of the pilot study and their impacts on the main study are reported in the 
chapter. The results and findings of the actual study are reported in narrative, tabular and figure 
formats. The chapter ends with a descriptive summary of the study interpretation and outcomes.   
Pilot Study 
The pilot study covered 53 days (see Figure 1 for the timeline), and targeted 30 
Physicians in the following specialties: seven family practitioners, four infectious disease/HIV 
specialists, seven internists, six obstetricians/gynecologists, and six pediatricians. There were 15 
females and 15 males randomly selected. Geographically, the participants were equally 
distributed, 15 participants in the Quad-Cities Illinois and 15 participants in Quad-Cities Iowa. 
This pilot test aimed to ask physicians to read and complete the questionnaire and give me 
feedback regarding items and instructions that they found unclear to understand.  
The participants answered to the following feedback questions after they had completed the 
survey: 





2. What is your interest in HIV PrEP issues?  
3. What is your understanding of the survey questions?  
4. Is the sequence of the questions encouraged or discouraged your desire to continue 
with the survey?  
5. Have you hesitated to answer any questions because you need clarification on some 
points?   
6. Was there anything objectionable in the survey?  
7. Is there anything in the survey that is not relevant or appropriate for your culture? 
8. Please, write down any wording that would have been clearer on the lines bellow.  
There were nine respondents out of 30 potential participants corresponding to a 30% response 
rate. Over 77% (7 out of 9) respondents said that they had a greater interest in HIV PrEP issues, 
whereas 11.11% had an interest in PrEP issues. More than 66% of the respondents had a good 
understanding of the survey, and 22.22% had a fair understanding. More than 88% of the 
respondents (i.e., 8 out of 9 people) said that the sequence of questions had encouraged them to 
continue with the survey. All of the respondents (100%) did not hesitate answer, find anything 
objectionable or needed clarification on any wording remarks in the data collection instrument.   
The feedback and comments from the participants showed the following: 
Survey Duration  
It took a minimum of 1 minute and a maximum of 5 minutes to complete the survey. The 
average time was 2 minutes and 30 seconds. I projected 2 to 5 minutes to complete the 







Interest in PrEP Issues 
Up to 66.67% of the respondents had a greater interest in the PrEP issues, 11.11% had an 
ordinary interest, and 11.11% had little interest. 
 
 Understanding of the Questions 
Up to 77.78% of respondents had a good understanding of the questions, 22.22% had a fair 
understanding, and 0% had a poor understanding. 
 
Sequence of Questions 
About 89% of respondents said that the sequence of the questions encouraged them to continue 
the survey. The answers were No for each of the following Yes or No questions regarding (a) 
participants’ hesitation to answer, (b) points that need clarifications, (c) anything objectionable, 
(d) anything not relevant/appropriate, and (e) any wording.  The spaces provided for the 
comments and remarks were left blank. I presented the results on Table 7. I also reported the 
timeline of the pilot study on Figure 3 and the summary of the pilot test and its inferences on 
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Data Report Showing Participants’ Responses (n = 9) 
1) How much do you known about HIV Pre-Exposure Prophylaxis 
(PrEP)? 
 
     Very 
      much 
Much Quite a 
bit 





0 1 2 3 0 3 0 0 
 
2) How often do you prescribe HIV PrEP? 
Very 
often 
Often Quite a 
bit 





0 1 0 0  8 0 0 
 
3) How long have you been served as a Physician? 
0 to 5 
years 
  6 to 10 
years 
11 to 15 
years 
16 to 20 years 21 to 25 years 26 years and 
more 
 






4) What is/are your specialty (ies)?  
 
Family Practice Infectious 
diseases 
Internist Ob/Gyn Pediatrician Other 
2 2 1 2 2 0 
 
5. A- Which of the following best describes your thoughts about prescribing PrEP? 
 
(a) I have never thought about prescribing PrEP to my 
 clients 
7 answers (77.78%) 
(b) I am undecided about prescribing PrEP to my clients 1 answer (11.11%) 
(c) I have decided; I do not want to prescribe PrEP to my 
 clients 
0 
(d) I have decided; I do want to prescribe PrEP to my clients 1 answer (11.11%) 
 
5. B- What is the most accurate reason you may not prescribe or propose PrEP services to 
 your clients who might need them? 
(a) I have never been in a situation that required me to prescribe or 
 propose HIV PrEP services to a client. 
(b) I don’t know much about PrEP and its guidelines/protocol to 
 prescribe or propose its services to my clients. 
(c) I think that only HIV specialists can prescribe HIV PrEP 
 
4 answers (44.44%) 
 









(d) I think that only HIV specialists can prescribe HIV PrEP 
 
























6.What is the age group range that do you belong to? 
 
     18 to 24 25 to 34 35 to 44 45 to 54 55 to 64 65 to 74 75 or older 
0 0 3 
(33.33%) 
5 (55.56%) 1 (11.11%) 0 0 
 
7.What is your gender at birth? 
Female Male 
3 (33.33%) 6 (66.67%) 
 












Pilot Test Summary and Inferences (n = 9)  





9 out of 30 30% I will expect about 30% response 
rate for the actual study 
 
Returned to Sender because 
the participants were no 
longer at the provided address 
or retired 
6 out of 30 20% I will expect about 20% of the 
surveys sent out to be returned to 
me for the actual study  because the 
participants might no longer at the 
provided address 
 
Some participants that did not 
respond  
15 50% I will expect about 50% of the 
participants that receive the survey 
effectively, will not fill and send it 
back to me during the actual study 
data collection process. 
  
Females responded 3 out of 15 20% I will expect more males to respond 
to the survey than females. 
Statistically, about 2/3 of the 
respondents will be male. 
Males Responded  6 out of 15 40% 
Responses from Illinois 5 out of 15 33.33% No zip code on one 







Results of the Pilot Study 
I presented the summary and inferences of the pilot study on Table 7. The returned 
responses exceeded the minimum number of height responses that was needed to consider the 
pilot study valid. The respondents did not suggest any corrections to the data collection 
instrument. However, there were several issues that I faced during the pilot study: 
 Difficulty finding the participants’ emails addresses to send them the Survey Monkey  
directly. Consequently, none of the respondents sent their responses via the Internet 
 Difficulty locating some physicians’ offices to hand out the questionnaires  
 Some participants have retired or moved to other locations outside the geographic study 
 area 
 Delay in time to return the completed surveys  
 Low response during the first month of the data collection. 
 
I requested a change in the data collection procedures to overcome the problems.  
The Institutional Review Board (IRB) allowed me to raise the number of the surveyed physicians 
from 19 to 30. IRB authorized me also to hand out the survey to the participants at their office 
via their receptionists to improve the response rate of the pilot study. Therefore, I resumed the 
pilot study data collection through an in-person distribution of the survey to eleven (11) 
additional physicians. IRB also authorized me to make a change to the sample population for the 
actual study. I increased it from 185 to 300 participants. I also use my car GPS system for 
direction purpose. Finally, the pilot study allowed me to make the following projections on the 





      1.   I expected about 30% response rate for the actual study 
      2.   I expected about 20% of the surveys sent out to be returned to sender because the   
            participants might no longer be at the provided address 
4. I expected about 50% of the participants who receive the survey, not fill it out and send  
      it back to me during the main study data collection process.  
5. There will be more males to respond to the survey than females. Statistically, about 2/3 of 
the respondents were expected to be males.   
       
One recommendation for self-improvement regarding the data collection of the main study was 
to find the ways to have the email addresses of the participants to facilitate the Internet-based 
survey participation. Unfortunately, it did not work out because I must buy the email addresses 
buy from a third party, which may violate the participants’ privacy and the research ethical rules.  
Data Collection of the Main Study 
I collected the data between October 24
th
, 2015 and January 24
th
, 2016 (i.e., 90 days). 
Three hundred surveys were mailed via US postal services. I also used In-person distribution 
approach to drop off the questionnaire at the Physicians’ offices.  Ninety-seven family 
practitioners, 44 pediatricians, 80 internists, 41 obstetricians/gynecologists, and 38 Infectious 
disease/HIV specialists were surveyed. One hundred responses were returned.  The response rate 
was 33.33% that was slightly greater than the 30% response rate of the pilot study. 
From the plan presented in Chapter 3, I noted four inconsistencies in data collection and 
analysis. The first inconsistency was the change in the procedures that I have requested during 
the pilot study to address low response issues that arose.  For example, the IRB allowed me to 





the main study. I calculated the actual sample size using Raosoft sample size calculator.  I chose 
30% as the percentage of the response distribution based on the 30% response rate projection of 
the pilot study. With 5% margin of error, 80% confidence level, and 1139 population size, the 
recommended sample size was n = 124 (Raosoft, n. d.).  Also based on the pilot study response 
rate of 30%, it was estimated that about 450 physicians would need to be contacted to obtain at 
least 144 responses. However, due to time and cost restraints the decision was made to survey 
300 physicians in the hope that a 50% response rate (higher than the pilot study response rate) 
could be obtained through follow-up with the potential participants. The study ended up with 
33.33% response rate, resulting in a sample size of n = 100.  
The IRB authorized me to use the in-person distribution approach to distribute the survey 
in some physicians’ offices via their receptionists. I used a car GPS system to locate the 
physicians’ offices. I prolonged the data collection period from two months to three, allowing me 
to collect more survey responses to scale up the response rate above the 30%. Two issues 
affected the response rate: a failure to send out the survey to the estimated 450 physicians and 
lack of participants’ email to encourage online participation through Survey Monkey.  
The second discrepancy was that no participant had used the Survey Monkey link provided in the 
invitation letter as planned. The third discrepancy was that I dropped the binary logistic for 
which the sample did not obey the normality assumption and used Kendall’s tau-b correlation 
test for the analysis of the research questions one and two. The final discrepancy was the usage 
of Fisher’s exact test (R x C) to analyze research question three instead of the ANOVA 
announced in Chapter 3. The change was necessary because the dependent variable (i.e., the 
frequency of PrEP prescription was a categorical that I changed into binary (high/low). It is not a 





3. Since I have two categorical variables, either chi-square (2x2) or Fisher’s exact test (R x C) is 
the appropriate test. Furthermore, I have more than two groups in the specialty category. I also 
observed low cell counts in the data. Therefore, Fisher’s exact test is the most suitable statistical 
test.   
Study Sample 
The survey sample included 300 Physicians or 26% from the 1,139 total physician 
population in the Quad Cities area and distributed across five specialties. The participants were 
evenly distributed across gender (150 females and 150 males) and geographic (150 participants 
from Illinois and 150 from Iowa). The final sample size was n = 100 or 8.7% of the total sample 
population, corresponding to the number of participants who completed the survey. I presented 
the distribution of the participants on Table 9.  
Table 9 
Response Rate Distribution Across Specialties (n =100) 
     Subpopulations Survey sample  Actual number of responses (n) 
 
Response rate 
     Family practitioners 
 
97 30 30.93% 
     Infectious disease /HIV 
 
     specialists  
 
38 11 28.95% 
     Internists 
 
80 17 21.25% 
     Obstetricians/ 
 
     gynecologists 
 
41 18 43.90% 
     Pediatricians  
 
44 19 43.18% 
     Total  300 100 33.33% 
      





















I used the IBM SPSS Statistics 21 for all statistical analysis. The key variables were 
coded and typed in the SPSS system. I conducted a series of descriptive statistics analyses. The 
first analysis was a frequency test for the respondents’ gender, geographic distribution, age (by 
category), years of experience (by category), and their specialty. There were N = 100 valid 
responses and zero missing data.   
I evaluated the zip code of respondents to determine their geographic location (i.e., 
Illinois versus Iowa). The five digits of the zip code of the Quad Cities Illinois start with 6, and 
that of the Quad Cities Iowa with 5. Table 4 reveals that slightly more participants lived in Iowa. 
The majority of participants were male. Many were 45 to 54 years old. The greatest number of 
them had 11 to 15 years of experience. Family Practitioners were more represented. The 
frequency distributions were presented on Table 10. 
Table 10 
Frequency distribution of demographic variables (n = 100) 
 
     Variables Frequency Percent 
     Gender of respondent   
     Male 53 53% 
     Female 47 47% 
     Age range of respondent   
     25-34 
13 13% 
 
     35-44 
21 21% 
 








     45-54 
31 31% 
 
     55-64 
28 28% 
 
     65-74 7 7% 
   
     Location of respondent   
     Illinois 48 48% 
     Iowa 52 52% 
     Year of experience of respondent   
     0-5 years 
14 14% 
 
     6-10 years 
16 16% 
 
     11-15 years 
20 20% 
 
     16-20 years 
14 14% 
 
     21-25 years 
18 18% 
 
     26 and more years 
 
     Specialty 
 
     Family practitioners 
 
     Infectious disease /HIV specialists 
 
     Internists 
 
     Obstetricians/gynecologists 
 



































The demographic characteristics of participants were represented on figures 4 – 8. 
 
Figure 4. Distribution of participants across gender. 
 
 







Figure 6. Age range distribution of participants. 
 
 







Figure 8. Distribution of participants across specialty. 
 
Information on other survey responses was summarized in Table 5. The majority of 
respondents had very little awareness of PrEP.  In addition, a higher number of them had never 
prescribed PrEP or thought about prescribing PrEP to their clients either. Furthermore, many 
participants declared that they don't know much about PrEP and its guidelines/protocol to 
prescribe or propose its services. See results on Table 11. 
Note. I redefined the dependent variable, the frequency of PrEP prescription as Prescription of 





Table 11  
Frequency and Percent of Survey Responses (n=100)  
 
How much do you know about PrEP? 
Response Frequency Percent (%) 
Very much 2 2% 
Much 1 1% 
Quite a bite 10 10% 
A little 32 32% 
Very little 36 36% 
None 18 18% 
Don't know 1 1% 
How often do you prescribe HIV PrEP? 









No answer 1 1% 







Response                                                        Frequency                                 Percent (%) 
I have never thought about 







I am undecided about 
prescribing PrEP to my clients 
 
23 23% 
I have decided; I do not want 





I have decided; I do want to 





Other opinions 2 2% 
What is the most accurate reason you may not prescribe or propose PrEP services to your clients 
who might need them? (Please check one) 
I have never been in a situation 
that required me to prescribe 










Response                                                        Frequency                                 Percent (%) 
   
I don't know much about PrEP 
and its guidelines/protocol to 
prescribe or propose its 
services to my clients 
 
53 53% 
I think that only HIV 




Insurance companies don't 




My clients cannot afford HIV 











I also presented these results in the pie chart format in figure 10.  
 
 
Figure 9. Level of PrEP awareness among participants. 
 
Next, to be consistent with the research method that I proposed in chapter 3, I 
reset the response data for the questions regarding awareness and prescription of PrEP 
into binary variables. The two components of the independent variable, awareness about 
PrEP, were low awareness coded 1 and high awareness coded 2. I defined low awareness 
as all answers that fall under (a little, very little, none, and don’t know).  The high 
awareness accounted for the answers that fall under (very much, much and quite a bit).  





PrEP coded no, and Prescribe PrEP coded yes. I considered the answers that fall under 
(none, and don’t know) for not prescribe PrEP. The answers that fall under very often, 
often, quite a bit, a little, and very little were categorized as prescribe PrEP. The 
frequency test was run for the two binary categorical variables. 
The results were presented in the pie chart formats on Figures 10 and 11 
Low Awareness Versus High Awareness About PrEP 
 
 





Eighty-seven percent of the respondents had low awareness about PrEP against 13% who 
had a higher awareness about PrEP.  
 
Prescribe Versus Not Prescribe PrEP 
Only 10% of respondents had prescribed PrEP against 90% who did not prescribe it. See 
results in Figure 11.  
 
 






Cross Tabulation Test to Compare the Frequency of PrEP Across Independent 
Variables 
I run a series of cross-tabulation analyses to compare the mean of the frequency of 
PrEP across provider types (specialties). Fisher’s exact tests were performed for all the 
other independent variables including awareness about PrEP, years of experience, and the 
covariates, gender and geographic locations (Illinois vs. Iowa) because I had cell counts 
that are less than 5 (Observed Values, n. d.). The results were presented in the Tables 12. 
Table 12 
Cross Tabulation Test of PrEP Prescription, Variables and Covariates (n=100) 
           Independent variables  Count for Prescribe versus Not 
prescribe PrEP 
P-Values for each 
Variable 


















    
Pediatrician 
    
 1 16  
  
Obstetrician/Gynecologist 
    
 3 13  
    
Infectious diseases/HIV 
specialist 
    
 6 13  







 Awareness    .017 




 High awareness  5 8  
 
 
Years of experience 
 
 
   
 
.002 































  .361 












  .460 









Two-sided Fisher's exact test revealed that the differences in the frequency of 
PrEP prescription across physicians’ specialties were not statistically significant. The 
differences occurred more frequently than expected by chance (P > 0.05, Fisher’s exact 
test). Inversely, there was statistically significant association between years of experience 
and the frequency of PrEP prescription (P = .002, two-sided Fisher's exact test). Pearson 
chi-square (χ2) test showed a significant association between awareness of PrEP and the 
frequency of PrEP prescription (p = .017). That between years of experience and the 
frequency of PrEP prescription was statistically significant too, confirming the result of 
Fisher’s exact test performed earlier. Gender difference and geographic location 
covariates were not associated with the frequency of PrEP prescription. The results of the 
frequency of PrEP prescription across other covariates were presented in the Figures 12 – 
17.  
 






Figure 13. Frequency of PrEP across age ranges of the participants.  
 
 







Figure 15. Frequency of PrEP prescription across gender (male versus female).  
 
 






Results by Research Question 
I checked whether or not the assumptions for logistic regression analysis were met to 
ensure that the data were suitable for this test. The assumptions include: 
1. Presence of dichotomous dependent variable, 
2. Presence of one or more independent variables, 
3. Ensure that the observations are independent, 
4. Ensure that the sample size is greater than 10 cases per variable (rule of thumb), 
5. Non multi-collinearity (Laerd Statistics, 2013) 
6. Normality.  
Observing the data set, I noticed that the first four assumptions were met for the 
following reasons. First, the dependent variable, the frequency of PrEP prescription was 
transformed into a dichotomous variable (i.e., prescribe PrEP, coded yes and not 
prescribe PrEP, and coded no. Second, I included in the study, one primary independent 
variable (awareness about PrEP) and many secondary independent variables or covariates 
(i.e., awareness of PrEP, years of experience, specialty, sex, age range, and location). 
Third, the responses provided for each question about the independent variables were 
independent of each other. Fourth, I observed more than ten (10) cases (i.e., 100 cases).  
I ran a series of collinearity diagnoses to test for no multi-collinearity assumption. 








Collinearity Diagnosis for Multi-Collinearity (n = 100) 
 
     Model Collinearity Statistics 
Tolerance VIF 
 
Locations (Illinois versus Iowa) 
.908 1.102 
 
What is your specialty? 
.997 1.004 
 
Gender (Male versus Female) 
.894 1.118 
 
Prescribe versus Not prescribe PrEP .985 1.015 
 







Collinearity Diagnosis for Multi-Collinearity of Frequency of PrEP (n = 100) 
     Model Collinearity Statistics 
Tolerance VIF 
 




Locations (Illinois versus Iowa) 
 
.901 1.109 
What is your specialty? .818 1.223 
   




Note. Tolerance > 0.10; VIF < 3 
 
For each collinearity analysis, the tolerance levels were very high (i.e., > 0.70), 
hence, greater than 0.10, the minimum tolerance level that indicates a presence of multi-
collinearity. All VIF values were very low (i.e., around 1.1), hence less than VIF = 3, 
considered as the minimum VIF value to conclude for the existence of multicollinearity 





I also run Kolmogorov-Smirnov test to check the normality of the model. I used a 
stepwise (i.e., enter method) and incorporated all variables. The results showed p-values 
= 0.00 for each of the variables. The p-value was less than 0.05, indicating that the 
variables do not follow a normal distribution (Ghasemi & Zahediasl, 2012). 
I transformed data using 1/x and x-squared. Next, I run Kolmogorov-Smirnov to 
recheck the normality of the transformed data. The results were statistically significant, 
showing that the sample does not follow a normal distribution. Consequently, logistic 
regression model is not appropriate for the analysis.  
Instead, I used Kendall’s Tau-b test (a nonparametric test) to analyze the research 
question one and question two. I used it as an alternative to Spearman’s rank-order 
correlation test whose monotonicity assumption was not met. Kendall’s Tau-b model, not 
only measures the strength of association between binary variables, but also it indicates 
the direction of the relationship (Laerd Statistics, 2013). The assumptions of Kendall’s 
Tau-b test were met; because, I can observe that the variables were continuous, and 
weighted on an ordinal scale. In addition, monotonicity is “not a strict assumption” for 
the model (Laerd Statistics, 2013). In a cancer study, Yao et al. (2007) used Kendall’s 
Tau-b test to find statistically “significant association between β1 integrin intensity score 
and fibronectin expression (Kendall's tau-b = 0.19; P = 0.03)” (Yao et al., 2007).  
 





What is the association between HIV PrEP awareness (independent variable) and 
the frequency of PrEP prescription (dependent variable) among primary care providers 
and HIV specialists in the Quad-Cities? 
Ho1: There is no association between HIV PrEP awareness and the frequency of  
PrEP prescription among primary care providers and HIV specialists in the Quad-Cities. 
Ha1: There is an association between HIV PrEP awareness and the frequency of 
PrEP prescription among primary care providers and HIV specialists in the Quad-Cities. 
 
Research question one was tested using Kendall's tau-b correlation test to 
determine the association between 100 physicians’ awareness of PrEP and the frequency 
of PrEP prescription among primary care providers and HIV specialists. There was a 
moderate, negative correlation between awareness of PrEP and the Frequency of PrEP 
prescription, which was statistically significant, (τb = - .367, p < .001). The negative 
value is an indication that the dependent variable and independent variable decrease 
collectively (What is Kendall's tau-b, 2016). Explicitly, the frequency of PrEP 
prescription decreases with the decrease of the physicians’ awareness about PrEP. I 







Kendall's tau-b Correlation Test of Association Detween Awareness of PrEP and PrEP 


















Sig. (2-tailed) . .000 
N 100 100 







Sig. (2-tailed) .000 . 
N 100 100 
**. Correlation is significant at the 0.01 level (2-tailed). 
I reject the null hypothesis. There is an association between HIV PrEP awareness and the 






Research Question 2  
What is the association between the number of years of service as a primary care 
provider or HIV specialist and the frequency of PrEP prescription among primary care 
providers and HIV specialists in the Quad-Cities? 
Ho2: There is no association between the numbers of years of service as a 
primary care provider and the frequency of PrEP prescription among primary care 
providers and HIV specialists in the Quad-Cities. 
Ha2: There is an association between the numbers of years of service as a primary 
care provider and the frequency of PrEP prescription among primary care providers and 
HIV specialists in the Quad-Cities. 
 
A Kendall's tau-b correlation test was run to determine the association between 
100 physicians’ years of experience and the frequency of PrEP prescription. The results 
presented in Table 16 showed a weak negative correlation between years of service and 
the Frequency of PrEP prescription, which was statistically significant (τb = - .228, p = 
.010).  The negative value shows that the frequency of PrEP prescription decreases when 






Kendall's tau-b Correlation test of Association Between Years of Experience and PrEP 
Prescription  
 
 Prescribe versus 
Not prescribe PrEP 
How long have 
you been served 











Sig. (2-tailed) . .010 
N 100 100 
How long have 
you been served 






Sig. (2-tailed) .010 . 
N 100 100 
*. Correlation is significant at the 0.05 level (2-tailed). 
 
I rejected the null hypothesis. There is an association between the numbers of years of 





Research Question 3 
What is the difference between provider types and the frequency of PrEP 
prescription among primary care providers and HIV specialists in the Quad-Cities? 
Ho3: There is no difference in provider types and the frequency of PrEP 
prescription among primary care providers and HIV specialists in the Quad-Cities.   
Ha3: There is a difference in provider types and the frequency of PrEP 
prescription among primary care providers and HIV specialists in the Quad-Cities.  
 
Fisher’s Exact test was used for research question 3 to examine whether there is a 
difference in provider types and the frequency of PrEP prescription among primary care 
providers and HIV specialists. 
Checking for Fisher’s Exact Assumptions 
 I have a small sample size N = 100. The participants to the survey are independent 
of each other. I also have two categorical variables and more than two groups (5 groups) 
in the specialty category. Therefore, Fisher’s exact test assumptions were met.  
 For information, one-way Analysis of Variance (ANOVA) was projected to 
analyze the research question three. However, the model did not fit because the 
continuity assumption one was not met. The dependent variable (i.e., the frequency of 
PrEP prescription) was not continuous. It was categorical that I changed it into binary 
(high frequency/low frequency). I have more than two groups in the specialty category 





the research question 3 over Kendall's tau-b correlation test that used to weight the 
research questions one and two. The research questions 1 and 2 focus establishing the 
association between the variables, and therefore align with Kendall’s Tau-b that “is a 
measure of association” (Non-parametric Measures, n. d.). On another hand, the research 
question 3 is about determining the difference in PrEP prescription among five 
specialties; therefore, fit into Fisher’s exact model that determine the difference within 
groups (Mehta & Patel, n. d.). Table 17 showed the cross-tabulation of the frequency of 



















Cross Tabulation of the Prescription of PrEP across Specialty (n = 100) 
 
 Specialty                      Count and Percent (%) Prescribe versus Not prescribe PrEP 
Prescribe PrEP Not prescribe PrEP 
 
Family Practitioner 
Count 3 30 
% within specialty 9.1% 90.9% 
% within Prescribe versus 




Count 1 16 
% within specialty 5.9% 94.1% 
% within Prescribe versus 
















Count 3 13 





















   
Count and Percent (%) Prescribe PrEP   Not Prescribe PrEP 
% within Prescribe versus 
Not prescribe PrEP 
 
       21.4% 15.1% 
Infectious diseases/HIV 
Specialist 
Count 4 14 
% within specialty 22.2% 77.8% 
% within Prescribe versus 




Count 3 8 
% within specialty 27.3% 72.7% 
% within Prescribe versus 




Count 14 86 
% within specialty 14.0% 86.0% 
% within Prescribe versus 
Not prescribe PrEP 
100.0% 100.0% 
 












Figure 17. Differences in the frequency of PrEP prescription across specialty.  
 
 
Based on Fisher’s Exact test, there was no statistically significant difference at 
0.05 significance level (p = .130). Therefore, I failed to reject the null hypothesis and 
conclude that there is no difference in specialty and the frequency of PrEP prescription 
among primary care providers and HIV specialists in the Quad-Cities. I summarized the 







Summary of the results of the PrEP study (n = 100) 
 
Research Questions  Statistical tests Results Conclusions 
RQ1: What is the 
association between HIV 
PrEP awareness and the 
frequency of  
PrEP prescription among 
primary care providers 








(τb = - .367, p < 
.001). 
I reject the null 
hypothesis. There is an 
association between HIV 
PrEP awareness and the 
frequency of PrEP 
prescription among 
primary care providers 
and HIV specialists in the 
Quad-Cities 
 
RQ2: What is the 
association between the 
number of years of 















I reject the null 
hypothesis. There is an 
association between the 







Research Questions                
 
provider or HIV 
specialists and the 
frequency of PrEP 
prescription among 
primary care providers 







(τb = - .228, p = .010) 
Conclusions 
 
service as a primary care 
provider and the  
frequency of PrEP 
prescription among 
primary care providers 
and HIV specialists in the 
Quad-Cities. 
RQ3: What is the 
difference between 
provider types and the 
frequency of PrEP 
prescription among 
primary care providers 






P = 0.130 
Null hypothesis is not 
rejected. There is no 
difference in provider 
types and the frequency 
of PrEP prescription 
among primary care 
providers and HIV 
specialists in the Quad-








The majority of the respondents had low awareness of PrEP. The frequency of not 
prescribing PrEP was very high. Ninety percent did not prescribe PrEP. About 60% have 
never thought about prescribing PrEP. The lack of awareness of PrEP and the lack of 
PrEP prescribing opportunities were the two primary reasons for physicians’ reluctance 
to prescribing PrEP. For example, more than the half of the participants do not know 
much about PrEP guidelines/protocol in order to prescribe or propose its services to the 
patients. About one-third of them had never been in a situation that required prescribing 
PrEP. Physicians who had higher awareness about PrEP prescribed it often compared to 
those who know only little about. Based on the cross-tabulation analysis, the physicians 
with many years of professional experience often prescribed PrEP. For example, the 
highest frequency of PrEP prescription was found among the physicians that have 26 and 
more years of experience, and the lowest frequency of PrEP prescription was found 
among the physicians that have 0-5 years of experience. Furthermore, infectious disease / 
HIV specialists prescribed more often PrEP. Physicians aged between 55 and 64 years 
old and more, prescribed PrEP very often.  Males more often prescribed PrEP compared 
to females. Geographically, the frequency of PrEP prescription was almost equally 
distributed across both Illinois and Iowa-Quad Cities areas.  
 Kendall's tau-b correlation analysis of the research question one showed a 





prescription (τb = - .367, p < .001). That of the research question two also revealed a 
statistically significant association between years of experience and the frequency of 
PrEP prescription (τb = - .228, p = .010). Regarding the research question three, Fisher’s 
Exact test showed p = 0.130, meaning that there was no statistically significant difference 
in provider types and the frequency of PrEP prescription among primary care providers 
and HIV specialists in the Quad-Cities.   
 In Chapter 5, I discuss the interpretation of the findings and conclusion of the 
results. I also discuss the limitations of the study, the implications for social change, and 






Chapter 5: Discussion, Conclusions, and Recommendations 
Introduction 
In this survey study, I aimed to explore the barriers to prescribing HIV PrEP and 
the need for education among care providers in the Quad Cities. The probability of 
contracting HIV is high among people who live in serodiscordant relationships. Securing 
a healthy sexual relationship was one of the top wishes of the serodiscordant sexual 
partners or couples (Heitz, 2015). PrEP was revealed 96% operative to decrease the risks 
of HIV infection in HIV-negative populations. However, the protocol of PrEP 
prescription is understood, causing under prescription among primary care providers and 
infectious diseases/HIV specialists (Carter, 2015). For these reasons, I proposed to test 
the hypothesis that awareness of PrEP, years of experience in the medical field, and 
provider types might be associated with the frequency of PrEP prescription among 
primary care providers and HIV specialists. To assess the level of PrEP awareness, and 
how often the care providers prescribe PrEP, I ran a series of frequency tests using SPSS. 
I used Kendall's tau-b correlation test and Fisher’s exact test to analyze the research 
questions. The findings showed that lack of awareness of and missing the opportunity to 
prescribe PrEP were the two primary barriers to prescribing PrEP at the care providers’ 
level. Kendall's tau-b correlation test revealed that there was a statistically significant 
association between awareness about PrEP and the frequency of PrEP prescription. The 





also statistically significant. Fisher’s exact tests showed non-significant differences 
between provider types and the frequency of PrEP prescription. In the following 
discussion, I describe the findings, compare them to those from the previous studies, and 
analyze them in the theoretical framework standpoint.  
Interpretation of the Findings 
I examined how HIV PrEP awareness, providers’ years of service, and provider 
types could be used as predictors of the frequency of PrEP prescription. Many types of 
research have been conducted on the barriers of prescribing PrEP at the client or patient 
level. However, literacy on PrEP provision among primary care physicians and HIV 
specialists is lacking. The findings of the dissertation research revealed a relationship 
between awareness about PrEP and the frequency of PrEP prescription. I also found that 
the relationship between the years of experience and PrEP prescription were statistically 
significant. There is no statistically significant difference in provider type and the 
frequency of PrEP prescription among primary care providers and HIV specialists in the 
Quad Cities. 
I discovered that the majority of respondents had low awareness about PrEP. 
Rosenthal et al. (2013) also found that the majority of physicians were unaware of the 
PrEP.  Similar to Krakower and Mayer (2013), I found that PrEP was underprescribed 
among primary care providers and infectious diseases/HIV specialists. I also discovered 
that the frequency of PrEP prescription was high among those who have high awareness 





(2013); Puro, et al., (2013); White et al., (2012). They found increased knowledge about 
PrEP associated with the rise in the frequency of PrEP prescription among primary care 
providers.  
In light of the observations described above, primary care providers and 
HIV/AIDS specialists’ disposition to prescribe PrEP depend on how much information 
and knowledge they have about PrEP. Moreover, providers’ readiness to prescribe PrEP 
and patients’ wiliness to adopt it should be the sine-qua-none conditions to promote PrEP 
regimen in the Quad Cities. However, I did not explore patients’ attitudes towards, and 
need of PrEP services in this study.  
The findings disconfirmed the assumption that the frequency of PrEP prescription 
is different as far as the physicians’ specialty. Furthermore, the results did not support the 
hypothesis that there is a difference in provider types and the frequency of PrEP 
prescription among primary care providers and HIV specialists. In addition, while 
Hoberg and Raymond (2013) found that high cost of PrEP could dissuade its prescribers 
and users, this study revealed that excessive cost and coverage of PrEP issues were not 
the primary barriers of prescribing it. Finally, the findings were opposite of the findings 
of Puro et al. (2013) that demonstrated that only HIV/AIDS specialists had a privilege to 
prescribe PrEP. In fact, this study showed that even non-HIV/AIDS specialists (i.e., 
family practitioners, internists, obstetricians/gynecologists, and pediatricians), had 





This study adds to the body of public health knowledge through the discovery that 
lack of awareness about PrEP and lack of opportunity are the primary barriers to 
prescribing PrEP at the physicians’ level. It provides insights that males are more likely 
to prescribe PrEP than females. It also shows equal distribution of the frequency of PrEP 
prescription across Illinois and Iowa.  
Theoretical Framework 
The principles of the PAPM as applied to this study include (a) identification of 
the seven stages of PAPM where physicians went through when prescribing PrEP and (b) 
definition of the factors that stimulate their movement from one stage to another. The 
results of the survey provided information on the physicians’ attitudes corresponding to 
each stage of the constructs of PAPM.   I observed the following: 
The majority of the respondents have never thought about prescribing PrEP (Stage 1: 
unaware).   
1. Twenty-three percent of respondents were unresolved about prescribing PrEP 
(Stage 3: undecided). 
2. Thirteen percent have decided that they want to prescribe PrEP (Stage 5: 
decided to act).  
3. Three percent have declared “do not want to prescribe PrEP” (Stage 4: 
decided not to act.), and 






Stage 1: Unaware 
About one-fifth of the physicians had never heard of PrEP. Therefore, they would 
never prescribe PrEP. There is a need for basic information (education) on PrEP to allow 
them to move to the next stages. 
Stage 2: Unengaged 
About 70% of the participants learned very little or a little about PrEP. However, 
they were not yet engaged due to underprescribing PrEP. Targeted education is desirable 
to make PrEP and the need for action personally important to unengaged physicians.  
Stage 3: Undecided  
About a quarter of the surveyed physicians were undecided about prescribing 
PrEP, meaning that they were engaged with the issue and looking for how to proceed. 
Since they did not yet form an opinion about prescribing PrEP, they would be less 
resilient to persuasion (DiClemente, Crosby, & Kegler, 2002). Therefore, technical 
training is necessary for undecided physicians.   
Stage 4: Decided Not to Act  
Less than 5% of the surveyed physicians said that they do not want to prescribe 
PrEP. I assumed these people were aware of PrEP but have unexpressed reasons that 
challenge their decision to prescribe it. DiClemente et al. (2002) stated that those 





On the other hand, some may hold off on deciding and stay undecided (Stage 3). 
Proactively identifying these barriers to PrEP education programs could help health 
educators to develop suitable strategies to overcome them.  
Stage 5: Decided to Act  
About 15% of the participants said that they plan to prescribe PrEP. I assumed 
that these individuals were conscious of the risks for not prescribing PrEP and the 
outcomes. Therefore, they decided to prescribe it. I used the data as baseline information 
to measure the percentage of physicians who are ready to prescribe PrEP in the Quad 
Cities area.  
Stage 6: Acting 
Ten percent of the surveyed physicians are prescribing PrEP. I also assumed that 
they might have some intrinsic and extrinsic motivations that I did not examine. 
Refreshment PrEP training might be needed to empower that target populations to 
continue prescribing PrEP 
Stage 7: Maintenance 
The study did not provide relevant data to quantify the number of physicians who 
have maintained their prescribing of PrEP over time. Further investigation of this aspect 






Limitations of the Study 
The physicians surveyed in this study did not represent a sample of all care 
providers that can prescribe PrEP in the United States. It included family practitioners, 
infectious disease/HIV specialists, internists, obstetricians/gynecologists, and 
pediatricians only. I might expand the sample to include other medical specialties such as 
physician assistants and certified nurse practitioners. Furthermore, the answers to the 
questions could be biased because of the self-reported survey (Yu & Tse, 2012). By 
aligning the survey questions strictly to the study’s theoretical framework context, I 
missed the opportunity to include a question that will help me to quantify the need for 
PrEP education among physicians with exactitude. I wish I added the following “yes” or 
“no” question to the survey questions: Do you want to learn more about PrEP? By 
default, I determined the need for PrEP education based on inference to answer b of the 
following survey question, “What is the most accurate reason why you may not prescribe 
or propose PrEP services to your clients who might need them?” (Please check one). I 
assumed that every participant who selected answer b, “I don’t know much about PrEP 
and its guidelines/protocol to prescribe or propose its services to my clients,” has 
implicitly expressed, a need for PrEP education. Therefore, the data may be misreported. 
The results of the pilot test of the survey instrument provided evidence that supports the 
reliability of the data collection tools.  
In Chapter 2 related to the literature review, I failed to report that the efficacy of 





usage of condoms only could not end HIV/AIDS pandemics, Thomson (2014) stated, 
“We have already lost the battle in condom use … condoms fatigue” (p.19). Therefore, a 
PrEP regimen that integrates steady and correct usage of condoms is recommended to 
prevent HIV transmission.     
The findings both confirmed and disconfirmed many results from the literature 
review on the concepts and key variables. For example, this study revealed the need for 
PrEP education and literacy improvement for physicians. Likewise, Krakower and Mayer 
(2012) showed that PrEP education enhancement within care providers is desirable to 
limit the higher HIV infection incidence rate in the United States. The findings also 
indicated that the majority of physicians do not prescribe PrEP because they do not know 
about its protocol. This confirms foundings from White et al. (2012) that 96% of 
physicians believed that formal PrEP guidelines from the CDC would increase their 
readiness to prescribe PrEP.  Similar to results of the literature review, this study revealed 
that PrEP was understood among primary care providers (Rosenthal et al., 2013).  
Whereas the literature review demonstrated the effectiveness of PrEP 
(Choopanya, et al., 2013; Paltiel et al., 2009), this study was limited to investigating the 
variance in the frequency of PrEP prescription among physicians. The literature review 
also found an association between stigma and PrEP prescription (Smith et al., 2012). 
However, I did not include stigma in the key variables of this study.  
In relation to inferences from the research data, the participants were randomly 





study (Creswell, 2009). Therefore, the study can be generalized to other care providers 
nationally and worldwide. Furthermore, the pilot tested survey instrument could become 
a reference for future researchers. 
Recommendations for Action and Future Study 
This research established a statistically non-significant difference in provider 
types and the frequency of PrEP prescription among the physicians from the five 
specialties engaged in the study. Therefore, I would recommend a study that includes 
other specialties or groups, such as physician assistants and nurse practitioners that can 
prescribe PrEP. I would also suggest using the odds ratio analysis to determine whether 
the probabilities of prescribing PrEP are similar for primary care providers and HIV 
Specialists. The actual study includes very small sample size. I would propose a 
quantitative study involving a large sample size. To better understand the barriers to PrEP 
prescription, I would suggest qualitative research through interviews and focus group 
discussions targeting physicians from different settings.  Further implementation research 
may be needed to understand and improve PrEP delivery at local and state levels. I would 
recommend using the results of this study to support or justify PrEP education and 
implementation grants projects. The findings can also inspire policies to regulate and 
update HIV/AIDS structural interventions. For example, it may be necessary to develop 
policies that support integrated PrEP implementation strategies. The strategies could 





process, and integrating PrEP referrals into partner services, STD clinics, and social 
network strategies. 
As a call for action to improve the frequency of PrEP prescription, I would 
recommend the following: 
 Create a PrEP center in the Quad Cities area and wherever there is a need to better 
identification of, and response to, under-prescribing of PrEP gaps; 
 Develop a comprehensive PrEP education curriculum that aligns to the precaution 
adoption process model for care providers nationwide;  
 Include PrEP topics into the continued education online training modules for all 
physicians, physicians assistants, and nurse practitioners; 
 Develop policies that support integrated PrEP implementation strategies. The 
strategies could consist of using HIV test to inform on PrEP, adding PrEP to risk 
assessment counseling process, integrating PrEP referrals into partner services, 
STD clinics, and social network strategies, and  
 Educate and train providers including case managers, outreach staff, and testing 
counselors about PrEP guideline, PrEP protocols, its advantages and limits.  
Finally, I would suggest taking PrEP information beyond care providers to the 
community as large trough community forums, community outreaches, seminaries, peer 







Implications for Social Change 
This study is of public health interest. By empowering care providers to prescribe 
PrEP more often to vulnerable populations including sex workers, persons in a 
serodiscordant relationship and others, the study will bring positive changes to 
individuals and their families. The direct impacts could include peace of mind and 
elimination of fear of the HIV infection. PrEP will not only bring new dynamics (i.e., 
confidence, psychological supports, love, harmony, sexual freedom, etc.) in the family of 
serodiscordant individuals but will also prevent new infections. Next, providing PrEP to 
the professional sex workers and multiple sex partners will reduce HIV infection in the 
community. At the organizational level, the study could add value to the public health 
educators’ efforts to advance the population health. It provides empirical data and a 
theoretical framework that HIV/AIDS prevention and treatment agencies/organizations 
can use for different purposes. Further, this study presents PAPM, as a potential 
evidence-based theoretical framework for the future PrEP interventions. The 
methodological approach could be a reference for many researchers, health educators, 
HIV/AIDS organizations and other public health professionals to advance research in the 
field.   
 
Conclusion 
Statistical analyses showed that there is an association between Prep awareness 





between awareness of PrEP and the frequency of PrEP prescription, may have been 
increased with the high PrEP awareness. I rejected the null hypothesis that “there is no 
association between the numbers of years of service as a primary care provider and the 
frequency of PrEP prescription among primary care providers and HIV specialists in the 
Quad-Cities” too. Therefore, the number of years of service as a primary care provider 
and the frequency of PrEP prescription were associated. The unknown was the maximum 
number of years of experience as a standard to predict the outcome of PrEP prescription 
among primary care providers and HIV specialists.  
I found no difference in provider type and Prep prescription. Infectious diseases 
and HIV/AIDS specialists prescribed PrEP more often than other specialties. About one-
third of HIV/AIDS frontline care providers have few opportunities to prescribe PrEP; 
whereas many other physicians are missing these chances in the United States (Carter, 
2015). The majority of doctors including family practitioners, internists, 
obstetricians/gynecologists and pediatricians had low awareness about PrEP. They had 
differences of opinion and practice regarding PrEP prescription. Primary care physicians 
believed that it was HIV/AIDS specialists’ responsibility to prescribe PrEP. Inversely, 
HIV/AIDS specialists thought that PrEP is a preventive approach and should be handled 
by primary care physicians.  
In the absence of an HIV vaccine, PrEP could become an indispensable tool to 
prevent HIV infection. Therefore, it is urgent to scale up PrEP prescription across the 





providing continued PrEP training to health care professionals. It is also important to 
provide physicians appropriate tools to detect persons at-risk for HIV infection, and 
encourage them to prescribe PrEP more often to these vulnerable persons. Ultimately, the 
results of this study indicate that physicians need education and training to fully 
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Appendix A : Pilot Project Survey Questionnaire  
 
PART 1 – DEMOGRAPHIC INFORMATION 
The information that you provide is only for statistical drive. I will remain confidential 
and anonymous. Your participation will be highly appreciated.  
1. Your area Zip Code is  
…………………………………………………………………….   
2. Your Gender (Please, circle one) 
- Male 
- Female   
3. What is your age? (circle that applied) 
- 18 to 24 
- 25 to 34 
- 35 to 44 
- 45 to 54 
- 55 to 64 
- 65 to 74 
- 75 or older                    
PART II – QUESTIONS ON HIV PrEP AWARENESS 
1) Tell me the number that shows how much you know about HIV Pre-Exposure 
Prophylaxis (PrEP).  (Please, circle that is applied to you.)                   
1. Very much   5. Very little 





3. Quite a bit    7. Don’t know 
4. A little    8. No answer 
 
TART III – QUESTION ON HIV PrEP PRESCRIPTION FREQUENCY 
2) Tell me the number that shows how often you prescribe HIV PrEP. (Circle that is applied 
to you.) 
1. Very often   5. Very little 
2. Often    6. None 
3. Quite a bit   7. Don’t know 
4. A little    8. No answer 
PART IV – QUESTION ON THE YEAR OF SERVICE AS A PRIMARY CARE  
  PROVIDER OR A HIV SPECIALIST  
3) How long have you being served as a primary care provider or a HIV specialist? (Circle 
the group that is applied to you.) 
a) 0 to 5 years 
b) 6 to 10 years 
c) 11 to 15 years 
d) 16 to 20 years 
e) 21 years and more  
PART V – QUESTION ON THE SPECIALTIES  
4) Circle all that applied to you: 
a) I am a family practitioner. 





c) I am an internist.  
d) I am an-obstetricians/gynecologists. 
e) I am an infectious disease specialist 
f) I am a HIV specialist 
g) Other (please, precise) ………………………………………………………………. 
PART VI – QUESTIONS ON HIV PrEP PRESCRIPTION ATTITUDE AND BARRIERS  
5) Which of the following best describes your thoughts about prescribing PrEP? (Circle that 
is applied)                    
a) I have never thought about prescribing PrEP to clients.          
b) I am undecided about prescribing PrEP to clients.              
c) I have decided I do not want to prescribe PrEP to clients.   
d) I have decided I do want to prescribe PrEP to clients. 
6) Select the most accurate reason (only one) why you might not prescribe or propose HIV 
PrEP services to your clients who might need it from the following: 
a) I have never been in a situation that required me to prescribe or propose HIV PrEP 
services to a client. 
b) I don’t know much about PrEP and its guidelines/protocol to prescribe or propose its 
services to my clients.  
c) I think that only HIV specialists can prescribe HIV PrEP. 
d) Insurance companies don’t want to cover HIV PrEP for my clients.  
e) Clients and or I have concerns about the HIV PrEP drugs’ side effects. 
f) My clients cannot afford HIV PrEP services because of the high cost.  
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